University of South Florida

Scholar Commons
Graduate Theses and Dissertations

Graduate School

January 2013

Computational Approaches for Structure Based
Drug Design and Protein Structure-Function
Prediction
Sai Lakshmana Kumar Vankayala
University of South Florida, svankaya@mail.usf.edu

Follow this and additional works at: http://scholarcommons.usf.edu/etd
Part of the Chemistry Commons, Computer Sciences Commons, and the Medicinal Chemistry
and Pharmaceutics Commons
Scholar Commons Citation
Vankayala, Sai Lakshmana Kumar, "Computational Approaches for Structure Based Drug Design and Protein Structure-Function
Prediction" (2013). Graduate Theses and Dissertations.
http://scholarcommons.usf.edu/etd/4601

This Dissertation is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in
Graduate Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact
scholarcommons@usf.edu.

Aum Sai Ram

Computational Approaches for Structure Based Drug Design and Protein
Structure-Function Prediction

by

Sai Lakshmana Vankayala

A dissertation submitted in partial fulfillment
of the requirements for the degree of
Doctor of Philosophy
Department of Chemistry
College of Arts and Sciences
University of South Florida

Co-Major Professor: Wayne Guida, Ph.D.
Co-Major Professor: H Lee Woodcock, Ph.D.
Mark McLaughlin, Ph.D.
Jianfeng Cai, Ph.D.
Priyesh Jain, Ph.D.

Date of Approval:
March 20, 2013

Keywords: Induced fit docking, Hydroxyurea, Hemoglobin, Catalase,
Alkylguanine transferase
Copyright © 2013, Sai Lakshmana Vankayala

Dedication

I dedicate this dissertation to my guru Sri Sathya Sai Baba, Hanuman, Dhanvantari and
my Devas. For all their guidance at every moment of my life, teaching me human values,
encouraging me, motivating me and reminding me of my life’s real purpose.

Acknowledgments
Matrudevo bhava, Pitrudevo bhava, Acharyadevo bhava.

Firstly I thank my parents, for providing me everything I need, without them this
work would not have been possible. Secondly I would humbly thank my major professor
Dr. Wayne Guida, for constantly supporting me, giving me complete freedom to work on
the research topic of my choice and motivating our research group with his personal
examples. I would like to thank my co-major professor Dr. H Lee Woodcock for all the
training he gave me in terms of rational thinking in conducting research, teaching the art
of scientific writing and spending hours to improve my presentation skills. I am grateful
for all the scientific learning received from both of you and above all for always being
there to help me. I am also grateful to my other committee members, Dr. Mark
McLaughlin and Dr. Jianfeng Cai for giving me their valuable advice and novel ideas to
improvise the quality of my work. Further, I would thank Dr. Jacqueline Hargis for all
her help in editing few of my chapters and improving the language.
I acknowledge my sister Shilpa for being there when I needed her. And I also
would like to acknowledge all the members of my Sai family for their prayers and well
wishes. Lastly, I would like to acknowledge my love, Ranjani Vankayala for all her
constant support, understanding and care throughout my life’s sojourn. Thanks for all the
Love.

Table of Contents

List of Tables ..................................................................................................................... iii
List of Figures .................................................................................................................... iv
List of Abbreviations ........................................................................................................ vii
Abstract ........................................................................................................................... viii
Chapter 1. In silco Structure Based Molecular Modeling Incorporating Receptor
Flexibility ............................................................................................................................ 1
1.1 Structure based drug design .............................................................................. 1
1.2 Molecular docking studies ................................................................................ 2
1.3 Scoring Functions ............................................................................................. 3
1.3.1 Force field based scoring functions ................................................... 3
1.3.2 Empirical scoring function ................................................................. 4
1.3.3 Knowledge based scoring function .................................................... 5
1.3.4 Consensus scoring function ............................................................... 5
1.4 Sampling Algorithms ........................................................................................ 6
1.4.1 Monte Carlo Conformational Search ................................................. 6
1.4.2 Genetic Algorithms ............................................................................ 7
1.4.3 Simulated Annealing .......................................................................... 7
1.4.4 Fragment based Ligand Sampling ..................................................... 7
1.5 Limitations ........................................................................................................ 8
1.6 Flexible docking studies ................................................................................... 8
1.6.1 Soft docking studies ........................................................................... 9
1.6.2 Semi-flexible docking studies .......................................................... 10
1.6.3 Fully flexible docking studies .......................................................... 11
1.6.4 Ensemble docking studies ................................................................ 12
1.6.5 Induced fit docking studies .............................................................. 13
1.6.6 Mutual adaptive coupled interaction studies.................................... 15
1.7 Conclusion ...................................................................................................... 17
Chapter 2. Unlocking the Binding and Reaction Mechanism of Hydroxyurea
Substrates as Biological Nitric Oxide Donors. ................................................................. 19
Note to the Reader ................................................................................................ 19
2.1 Abstract ........................................................................................................... 19
i

2.2 Introduction ..................................................................................................... 20
2.3 Methods........................................................................................................... 25
2.3.1 Protein and ligand/substrate preparation .......................................... 25
2.3.2 Customized Induced Fit Docking .................................................... 26
2.4 Results ............................................................................................................. 28
2.5 Discussion ....................................................................................................... 32
2.6 Conclusion ...................................................................................................... 40
2.7 Acknowledgements ......................................................................................... 42
Chapter 3: How Does Catalase Release Nitric Oxide? A Computational Structure
Activity Relationship Study .................................................................................................. 43
3.1 Abstract ........................................................................................................... 43
3.2 Introduction ..................................................................................................... 44
3.3 Computational Details .................................................................................... 49
3 . 4 Results and Discussion ................................................................................... 52
3. 4. 1 IFD results for all HUA's : .............................................................. 57
3.4.2 Proposed mechanism of action ........................................................ 65
3.4.3 IFD dockings incorporating prime minimization ............................ 69
3.4.4 Insights into the most likely mechanism of action........................... 71
3.5 Conclusions ..................................................................................................... 73
3.6 Acknowledgments........................................................................................... 74
Chapter 4: Computational correlation studies towards inactivation of O6alkylguanine-DNA alkyltransferase by O6-benzylguanine analogs ................................. 75
Note to the Reader ................................................................................................ 75
4.1 Abstract ........................................................................................................... 75
4.2 Introduction ..................................................................................................... 76
4.3 Methods........................................................................................................... 79
4.4 Results and Discussion ................................................................................... 81
4.5 Conclusion ...................................................................................................... 88
4.6 Acknowledgments........................................................................................... 91
Bibliography ..................................................................................................................... 92
Appendices ...................................................................................................................... 108
Appendix A. Supporting information and copyright permissions for
chapter 2 ........................................................................................................ 108
A.1 Analysis of second low energy pose ................................................ 108
A.2 Sequence alignment studies ............................................................. 110
A.3 Permissions ...................................................................................... 111
Appendix B. Supporting information for catalase work ..................................... 112
Appendix C. Chapter 4 permissions ................................................................... 115

ii

List of Tables
Table 2-1: XP descriptor analysis derived from IFD-XP redocking of hydroxyurea
analogs into OxyHb, compared with the reported experimental rate constants. ............29
Table 2-1A: Summary of IFD studies of hydroxyurea analogs leading to
conformational movement of residues .........................................................................30
Table 2-2: XP descriptor analysis of all hydroxyurea analogs obtained from IFDXP redocking in MetHb. .................................................................................................31
Table 2-2A: Summary of IFD studies of hydroxyurea analogs leading to
conformational movement of residues (RMSD values, Å) in MetHb ...........................32
Table 2-3: XP descriptor analysis of 6, 6a and 7 obtained from IFD-XP docking in
MetHb. ............................................................................................................................36
Table 3-1: XP descriptor analysis showing the contribution of various GlideXP
terms in kcal mol-1 for all pose A and pose B conformations of HUA’s. .......................56
Table 3-1A: Summary of IFD refinement binding orientaions (# corresponds to
number of) .......................................................................................................................57
Table 3-2: Summary of flexible docking studies of HUA’s that caused the
following residues to undergo substantial conformational movements ..........................58
Table 3-3: B3LYP/6-31G DFT study of the torsional potentials for Nhydroxyurea radical. .......................................................................................................70
Table 3-4: Summary of IFD prime minimization orientations (# corresponds to
number of) .......................................................................................................................71
Table 4-2: Docking parameters derived from docking compounds 1-3, 5-7, O6benzylguanine and O6-methylguanine to human alkyltransferase. .................................85

iii

List of Figures

Figure 1-1: Flowchart displaying the prime concerns consisting of ligand
sampling, scoring function, and flexible docking studies. ................................................3
Figure 1-2: Flowchart describing the different types of flexible receptor docking
approaches.........................................................................................................................9
Figure 2-1: Generic representation of various oxidation states of Iron that exist in
human adult hemoglobin.................................................................................................22
Figure 2-3: Generic reaction scheme presented by King and co-workers .........................24
Figure 2-4: The flowchart of IFD protocol followed to predict the binding modes
of hydroxyurea analogs in OxyHb and MetHb. ..............................................................28
Figure 2-6: IFD structures for predicted binding modes of the hydroxyurea
analogs, 1, 7 and 8 in MetHb are depicted in 6a, 6b and 6c, respectively. .....................31
Figure 2-7: Proposed mechanism of action between hydroxyurea analogs and
adult hemoglobin ............................................................................................................33
Figure 2-8: Comparison of the induced fit conformation of OxyHb with 5 (in dark
green) and apo structure of OxyHb (in yellow).. ............................................................35
Figure 2-9: Mutiple sequence alignment studies of human globin chains using
Clustal W2 in which 2DN1-A is used as the query protein ............................................38
Figure 3-1: Hydroxyurea analogs tested for their structure activity relationship by
King and co-workers in hemoglobin. ..............................................................................45
Figure 3-2: Proposed reaction mechanism by Fita and Rossmann, for H2O2
interaction with catalase CpdI.. .......................................................................................47
Figure 3-3: Generic representation of catalase mediated NO production from
hydroxyurea by King and co-workers.. ..........................................................................48
iv

Figure 3-4: Inter-molecular hydrogen bonding network observed for the H2O2
docking orientation in catalase CpdI active site.. ...........................................................53
Figure 3-5: Predicted pose A binding orientations of hydroxyurea analogs 1(5a)
and 8(5b) in catalase CpdI.. ...........................................................................................55
Figure 3-6: Predicted binding orientations of hydroxyurea analogs 1(6a), 7(6b)
and 8(6c) for pose B conformations in catalase CpdI. .....................................................55
Figure 3-7: 2D interaction energy diagram depicting the per residue interactions
between pose A and pose B conformations of hydroxyurea analogs with CpdI ............60
Figure 3-8: 2D interaction diagram depicting the per residue interactions for
hydroxyurea analogs 3, 4 and 7 with catalase CpdI ........................................................61
Figure 3-8A: Predicted binding orientations of HUAs 3, and 4 pose conformations
in catalase CpdI. ..............................................................................................................62
Figure 3-9: Predicted a)pose A and b)pose B binding orientations of 5 in catalase
CpdI.................................................................................................................................63
Figure 3-10: Proposed reaction mechanism for HUA interaction with catalase
CpdI for pose A orientations.. .........................................................................................66
Figure 4-1: Direct reversal pathway repairing DNA damage by reversing the
alkylation on O6-guanine. ...............................................................................................77
Figure 4-2: Substituted O6-benzylguanines and an N6-[(hydroxymethyl)benzyl]-2aminoadenine resulting from a rearrangement of 3. .......................................................79
Figure 4-3: Prepared protein of the human alkyltransferase without DNA. O6methylguanine and WAT1 also shown. ..........................................................................80
Figure 4-4: Plot of log(ED50) values versus QPLD_Glide_scores. Numbering
corresponds to compounds listed in Table 3. ..................................................................84
Figure 4-5: Plot of log(ED50) values versus E-Model scores. Numbering
corresponds to compounds listed in Table3. ...................................................................84
Figure 4-6: The key hydrogen bonding interactions of compound 2 (O6-[3(aminomethyl)benzyl]guanine) with the protein residues ..............................................86

v

Figure 4-7: Overlay of the position of all of the docked compounds in the human
alkyltransferase active site with the native ligand O6-methylguanine and others ..........87
Figure 4-8: AGT activity remaining (%) at 200 uM of the following NSC drugs ............88
Figure 4-9: The key hydrogen bonding interactions of streptonigrin (NSC 45383)
with the protein residues represented in stick model. .....................................................90
Figure A-1: Generic representation of second lowest energy pose for all
hydroxyurea analog IFD structures, 8 is shown as an example. ..................................108
Figure A-2: Image retrieved from local structure similarity profile webpage
for Adult Hemoglobin (HbA) protein (PDB/Chain ID: 2DN1/A). .............................109
Figure A-3: Mutiple sequence alignment studies of human globin chains
includes using ClustalW2 in which 2DN1-A is used as the query protein. ..........110
Figure B-1: Predicted binding orientations of hydroxyurea analogs (3, and 4) pose
conformations in catalase CpdI. ....................................................................................112
Figure B-2: Modified analogs of 6 along with7..............................................................112
Figure B-3: Predicted binding orientations of hydroxyurea analogs (6a, and 6b)
that gave pose A like conformations in catalase CpdI ..................................................113
Figure B-4: Hydroxylamine reaction with catalase to produce HNO..............................113
Figure B-5: Torsional angle Vs Energy plot ....................................................................114

vi

List of Abbreviations

IFD

Induced fit docking

SCD

Sickle cell disease

HUA

Hydroxyurea analog

NO

Nitric oxide

OxyHb

Oxy hemoglobin

DeoxyHb

Deoxy hemoglobin

MetHb

Methemoglobin

Cpd I

Catalase compound I

AGT

O6 –alkylguanine-DNA alkyltransferase

vii

Abstract
This dissertation thesis consists of a series of chapters that are interwoven by
solving interesting biological problems, employing various computational methodologies.
These techniques provide meaningful physical insights to promote the scientific fields of
interest. Focus of chapter 1 concerns, the importance of computational tools like docking
studies in advancing structure based drug design processes. This chapter also addresses
the prime concerns like scoring functions, sampling algorithms and flexible docking
studies that hamper the docking successes. Information about the different kinds of
flexible dockings in terms of accuracy, time limitations and success studies are presented.
Later the importance of Induced fit docking studies was explained in comparison to
traditional MD simulations to predict the absolute binding modes.
Chapter 2 and 3 focuses on understanding, how sickle cell disease progresses
through the production of sickled hemoglobin and its effects on sickle cell patients. And
how, hydroxyurea, the only FDA approved treatment of sickle cell disease acts to subside
sickle cell effects. It is believed the primary mechanism of action is associated with the
pharmacological elevation of nitric oxide in the blood, however, the exact details of this
mechanism is still unclear. HU interacts with oxy and deoxyHb resulting in slow NO
production rates. However, this did not correlate with the observed increase of NO
concentrations in patients undergoing HU therapy. The discrepancy can be attributed to
the interaction of HU competing with other heme based enzymes such as catalase and
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peroxidases. In these two chapters, we investigate the atomic level details of this process
using a combination of flexible-ligand / flexible-receptor virtual screening (i.e. induced
fit docking, IFD) coupled with energetic analysis that decomposes interaction energies at
the atomic level. Using these tools we were able to elucidate the previously unknown
substrate binding modes of a series of hydroxyurea analogs to human hemoglobin,
catalase and the concomitant structural changes of the enzymes. Our results are consistent
with kinetic and EPR measurements of hydroxyurea-hemoglobin reactions and a full
mechanism is proposed that offers new insights into possibly improving substrate binding
and/or reactivity.
Finally in chapter 4, we have developed a 3D bioactive structure of O6alkylguanine-DNA alkyltransferase (AGT), a DNA repair protein using Monte Carlo
conformational search process. It is known that AGT prevents DNA damage, mutations
and apoptosis arising from alkylated guanines. Various Benzyl guanine analouges of O6methylguanine were tested for activity as potential inhibitors. The nature and position of
the substitutions methyl and aminomethyl profoundly affected their activity. Molecular
modeling of their interactions with alkyltransferase provided a molecular explanation for
these results. The square of the correlation coefﬁcient (R2 ) obtained between E-model
scores (obtained from GLIDE XP/QPLD docking calculations) vs log(ED)values via a
linear regression analysis was 0.96. The models indicate that the ortho-substitution causes
a steric clash interfering with binding, whereas the meta-aminomethyl substitution allows
an interaction of the amino group to generate an additional hydrogen bond with the
protein. Using this model for virtually screening studies resulted in identification of

ix

seven lead compounds with novel scaffolds from National Cancer Institute Diversity
Set2.

x

Chapter 1. In silco Structure Based Molecular Modeling
Incorporating Receptor Flexibility
1.1 Structure based drug design
The central goal of drug discovery involves lead optimization of small molecules
that favorably regulates the enzymes biological activity. Most pharmaceutical companies
use wet-lab based high throughput screening (HTS) for detection of novel lead
compounds. However, these drug development processes are time consuming, expensive,
and have low hit rates, which led to the development of cost effective in-silico type
structure based drug designing techniques.1

Structure based drug design (SBDD)

techniques rely on a high resolution 3D bioactive protein structures obtained through
experimental

techniques

like

X-ray

crystallography

or

NMR.

Alternatively,

computational homology modeling can create these if experimental 3D structures are not
available. Subsequently, various small molecule libraries are virtually screened in protein
active-site and the approximate binding affinities are estimated with the help of in silico
drug design tools such as docking programs. Further, low-energy compounds with good
complementary interactions are screened based on visual inspection, virtual ADME
calculations, and Lipinski’s rule of five. Following this procedure, the top scoring
compounds are produced from chemical vendors or synthesized in the laboratory for
biological testing.2 Once the lead compound is identified, structure activity relationship
(SAR) studies are performed to improve the biological activity of the lead compound.
1

Finally, the whole SBDD process is reiterated but focused libraries similar to the lead
compound are used with advanced docking tools to best obtain the ideal drug candidate.
1.2 Molecular docking studies
Docking studies play a critical role in the development of novel drugs with unique
molecular scaffolds in SBDD efforts including virtual screening studies. For over 20
years3 docking studies have been primarily used for predicting correct binding poses and
estimating approximate binding affinities by scoring interaction energies between the
protein x-ray crystal structure and small molecules of interest. Initial docking studies
were based on the lock and key theory proposed by Emil Fischer,4 in which the ligands
are bound to a protein receptor in a lock and key fashion. This docking protocol treats
both the ligand and receptor as rigid bodies, however current developments include
ligand flexibility in programs such as Glide,5 GOLD,6 AutoDock,7 and FlexX.8 The
primary goals of docking studies are predicting experimental binding modes, identifying
false positives from true binders and predicting absolute binding free energies for a given
ligand library. However, despite the development of over 60 docking programs9 the
attempts to use a universal docking program to satisfy these goals are difficult. These
limitations arise due to various factors like approximations used in docking programs,
inadequate sampling of ligand degrees of freedom, validation of docking programs using
only limited protein-ligand data sets, not accounting for protein flexibility, and scoring
function issues in handling metals, co-factors, covalent interactions, explicit water
molecules etc.3 However, addressing limitations such as scoring function, sampling
algorithms, and receptor flexibilities remain active areas of research.

2

Figure 1-1: Flowchart displaying the prime concerns consisting of ligand sampling,
scoring function, and flexible docking studies.
1.3 Scoring Functions
One of the primary objectives of a scoring function is to estimate the relative
binding energies of small molecules to the protein active site and rank their putative
binding affinities. One scoring function limitation is the ineffectiveness to predict
absolute binding free energies due to simplification and approximations to save on
computational time. Development of scoring functions remains an active area of research
to increase accuracy, namely to discriminate true binders from false positives in virtual
screening studies. Scoring functions are classified into four basic schemes which are
Force field, Empirical, Knowledge, and Consensus based scoring functions.
1.3.1 Force field based scoring functions: Force field based scoring functions (FFSF)
rely upon molecular mechanics type methods that are fundamentally used to calculate the
intermolecular interactions such as bonds, angles, improper torsions, dihedrals and
intramolecular/intermolecular non-bonded interactions like van der Waals, electrostatics,
and ligand strain energies.10 Most of the current FFSF are simplified by neglecting
protein internal energy calculations but may include ligand strain energies induced upon

3

ligand binding to the protein. Generally, electrostatic terms are accounted by Columbic
potential using a distance dependent dielectric function. The van der Waal terms are
governed by a Lennard-Jones potential that controls both repulsive close contacts
sometimes referred to as “hardness” of intermolecular forces and long range attractive
forces. The standard FFSF, have certain limitations like high computational cost, and lack
of solvation and entropy terms. Moreover, the long range non-bonding interactions
cannot be treated accurately due to the arbitrary selection of cut-off distances.11 However,
the current progress in FFSF include: hydrogen bonding interactions, solvation, and
torsional entropy terms. And some examples of docking programs that use FFSF are
GOLD6 and Autodock.7 Recent developments include solvation incorporate treating
water as a continuum dielectric medium.10 Poisson-Boltzmann/Surface Area (PB/SA) and
Generalized Born/Surface Area (GB/SA) are the common examples of implicit solvent
models recently included in the DOCK program.12
1.3.2 Empirical scoring function: The empirical scoring function is parameterized using
experimental binding free energies that consist of the sum of weighted interaction energy
terms. The weighing factor or the co-efficient of various energy terms are obtained by
regression analysis of experimentally available binding energies and binding geometries
from molecular training sets of 3D protein bioactive structures.13,14 Empirical scoring
functions (EF) are very similar to FFSF’s, however, they include additional interaction
energy terms like hydrophobic, hydrogen bonding, entropy, ligand strain, metal-ligation
and π-π stacking interactions. Popular empirical scoring functions are ChemScore, Glide,
and LUDI.5,15,16 Empirical scoring functions are limited in accuracy due to limited
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training sets used and it is unclear how well it is suited to model intermolecular forces
across the proteome.
1.3.3 Knowledge based scoring function: The knowledge based pair-wise potentials
(KSF) are generated using the reverse Boltzmann potential construction method.17 This
employs the statistical analysis of pairwise atomic interactions using experimental 3D
bioactive structures. The scoring functions are built on the assumption that the stronger
the complementary interactions, the more likely their statistical occurrence would be.
Based on this statistical analysis the knowledge based scoring functions scores favorable
contacts and penalizes low statistical occurrences from biomolecular interatomic forces.
These KSF can do an excellent job in modeling binding contributions such as solvent
effects, conformational entropy, interaction enthalpy,17 and rare interactions like cation-π
and sulphur-aromatic interactions that remain a challenge for classical force fields.11
However, like ESFs even the KSFs are limited in accuracy due to limited
parameterization resulting from small training sets of 3D bioactive structures. Moreover,
KSFs have problems dealing with metals and halogens. Some common examples of
KSFs used in docking methods are SMoG,18 PMF,19 Gold/ASP,20 and Kscore.21
1.3.4 Consensus scoring function: Imperfections of other scoring functions in terms of
accuracy and aspirations for a universal scoring function have lead researchers to develop
consensus scoring functions (CSF). In order to maximize advantages and minimize
deficiencies, CSF combines information from different scoring functions. Moreover, the
CFS’s primary objective is to improve the enrichments in virtual screening studies to
identify the true binders from false positives. However, CFSs often can underestimate the
binding affinities if it is built upon a combination of highly correlated scoring functions.
5

Various CFSs include MultiScore,22 X-Cscore,23 Cscore24 etc. are used in current docking
programs. The popular CFS X-Cscore combines scoring functions of Gold, Dock,
ChemScore, PMF and FlexX.25
1.4 Sampling Algorithms
Ligand sampling is one of the most important prerequisites for successful
application in docking studies by searching all possible ligand degrees of freedom to
capture the experimental binding orientation. Sampling algorithms need to be robust
enough to generate all putative ligand orientations to capture the experimentally solved
binding modes in the protein active-site. Presently, the docking programs employ ligand
sampling by two possible strategies: whole molecule and fragment based sampling
approaches. The majority of sampling methods use the whole molecule approach to
sample the pose space. Further, whole molecule methods produce pre-calculated ligand
conformations by Monte Carlo (MC), Molecular Dynamic simulations (MD), Genetic
algorithms (GA), and simulated annealing (SA) techniques.
1.4.1 Monte Carlo Conformational Search: MC based algorithm searches the ligand
conformational space through random torsional sampling of rotatable bonds. These new
sets of conformations are generated by satisfying an energy based criterion after initial
perturbations. This method is superior to MD in exploration of search space by crossing
the high energy barriers on the potential energy landscape. Many docking programs like
Glide,5 Rosetta Ligand,26 and ICM27 employ MC sampling for generating pre-determined
ligand conformations.

6

1.4.2 Genetic Algorithms: The underlying theory of these methods comes from Charles
Darwin theory of evolution. The ligand translational, rotational, and torsional degrees of
freedom are treated as genes with corresponding energies. The mutation of this gene
generates a new pose based on an energy fitness scheme. The exploration of the complete
genome would give us the potential energy landscape along with the global energy
minimum of the ligand pose. Many docking programs employ genetic algorithms for
ligand sampling inclusing GOLD,6 DIVALI,28 and AutoDock.7,29
1.4.3 Simulated Annealing: These methods allow the exploration of the global minimum
by escaping the local minima via crossing local energy barriers through a temperature
controlled Metropolis criterion algorithm. This method involves heating the ligand to a
high temperature and cooling it slowly to obtain the preferred conformational states of
the ligand. This is a stochastic algorithm as a random population of ligand conformations
are produced in different attempts, in spite of the exact cooling conditions. Earlier
versions of AutoDock7,29 used the simulated annealing approach.
1.4.4 Fragment based Ligand Sampling: This method entails dissecting the ligand
molecule into several fragments: a base fragment and flexible fragments. The base
fragment is docked first in optimal orientation to establish favorable complementary
interactions. Later, the incremental reconstruction of flexible fragments is undertaken in a
stepwise manner to explore all possible bond rotational search space that confers ligand
elasticity. Moreover, unreasonable conformations are discarded at the early stage using a
pruning algorithm to save on computational time.25 This method can further be extended
to de novo design programs by constructing newer ligands by altering the bond
connectivity of the parent ligand using incremental construction algorithms.14 Various
7

docking programs like FlexX,8 Hammerhead,30 and DOCK12 use fragment based ligand
sampling methods.
1.5 Limitations
Despite recent developments in scoring functions and ligand sampling algorithms,
several challenges still exist with rigid docking strategies. One such limitation would be,
ligand size greater than ten rotatable bonds, which poses a greater challenge to obtain the
correct ligand conformation. Likewise, exhaustive ligand sampling protocols, in an
attempt to capture the true binding mode can sometimes lead to unnecessary
conformational exploration that drains computational resources. Further, it was shown
that rigid receptor dockings cannot reproduce experimental binding modes for 50-70 % of
the ligand docking studies.31 Many cross docking experiments have shown that the
docking accuracy drops when an alternative protein conformation is used other than the
true protein conformation. Abagyan and co-workers used a set of 33 protein kinases in
cross docking studies and found a decrease in docking accuracy by 30%.32 Hence current
research is focused on developing methods that evaluate protein degrees of freedom
along with ligand sampling to solve the flexibility issues for predicting correct
experimental binding modes.
1.6 Flexible docking studies
David Koshland was the first to expand upon the flexible protein – flexible ligand
initiative by introducing the induced fit theory.4 Additionally, it has become evident that
proteins in the biological systems undergo dynamic motions ranging from bond
vibrations, torsional rotations, hinge bending, loop refinements, allosteric regulations, and
large scale domain motions.31 Further, the plethora of available 3D X-ray and NMR
8

structures indicates that protein flexibility results from intrinsic disorder or from ligand
induced adaptions. Many of these dynamic forces influence binding orientations of small
molecule ligands by forming various complementary interactions due to protein
flexibility. Hence, many flexible docking methods have been developed to confer protein
degrees of freedom under three main categories: soft docking, side-chain sampling or full
protein flexibility.

Figure 1-2: Flowchart describing the different types of flexible receptor docking
approaches.
1.6.1 Soft docking studies
A previous attempt to include protein plasticity in rigid docking studies was
derived from soft potentials allowing a certain degree of steric fitting between the ligand
and the protein binding site. Jiang et. al, were the first to explore the soft docking
approaches in order to augment the complementary interactions between a protein-ligand
complex, otherwise not possible with apo crystal structures.33 They developed a
molecular docking protocol using a cube representation describing molecular surface and
volume. Geometric docking they used is based on the shape and size structural
complementarity between protein-ligand interface using soft potentials that generates an
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ensemble of structures. Later they screened and filtered these complexes based on
favorable energy cutoffs to get subpopulations of these complexes. They applied this
method using trypsin complexed with a trypsin inhibitor using PDB: 2PTC and redocked
random orientations and obtained experimental binding modes. Recent strategies for soft
docking methods involve manipulating the scoring function.

The modification of

repulsive van der Waals interactions of the protein-ligand complex is performed by
replacing the Lennard-Jones 12-6 potentials with 9-6 potentials.34 Docking programs like
GOLD6 uses the Lennard Jones 8-4 potentials and AutoDock29 uses smooth potentials in
their soft docking approaches. Soft docking studies are computationally efficient and fast
as they take the same amount of time as rigid docking studies. Using these soft potentials,
Ferrari et al. screened the Available Chemical Directory (ACD) small molecules to the
T4 lysozome which resulted in better enrichments compared to hard potential based
docking.34 They found that docking to multiple receptor conformations of aldose
reductase led to the production of 6 inhibitors, which are poorly scored in their soft
docking approach. Likewise, they had limited success due to minor side-chain movement
and eventually steered the development to other semi-flexible methods.
1.6.2 Semi-flexible docking studies
Semi-flexible docking methods generate specific degrees of freedom by dynamic
sampling of side-chains keeping the backbone fixed during the simulations. Leach35
introduced earlier methods for incorporating side-chain sampling by generating discrete
low energy intermolecular protein conformations using rotamer libraries. At around the
same time, Abagyan et al. developed the internal coordinate method (ICM) that samples
receptor side chains using a Brownian Monte Carlo minimization, which includes
10

solvation and surface tension in the internal coordinates space of the protein complex.27,36
They used the GCN4 transcriptional activator PDB X-ray crystal structure to dock
flexible Leucine zipper helices of 31 residues and obtained strong intermolecular parallel
helices with a root mean square deviation of 1.18 Å from the experimentally derived
structure. Recently, Dean and co-workers37 used random side chain torsional angles χ
instead of rotamer libraries to incorporate receptor side-chain flexibilies in their docking
program SkelGen. They employed a SA protocol to sample side-chains during ligand
docking to the active-sites of acetylcholinesterase and matrix metalloproteinase-1 and
concluded its safe to use random torsional angles without using rotamer libraries. Other
popular docking programs that use flexible side-chain protocols are AutoDock 4,38 and
FDS.39
1.6.3 Fully flexible docking studies
For highly flexible receptor sites, current computational techniques can induce
full flexibility of protein-ligand interactions by three ways: ensemble docking, induced-fit
docking and mutual adaptive coupled interaction studies. These tools are classified based
on the characteristic differences of whether the ligand binds before, after or during the
protein conformational changes. If the ligand chooses the pre-existing ligand boundprotein conformational states then it is classified as ensemble dockings. However, if
protein structural changes are induced upon ligand binding then induced-fit docking is
used. Finally, protein-ligand conformational changes happen simultaneously, mutual
adaptive coupled interactions studies are used to explore the protein-ligand
conformational degrees of freedom concurrently.
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1.6.4 Ensemble docking studies
Proteins are dynamic entities existing in a diverse set of conformational states
populated in dynamic equilibrium. Many researchers believe that ligands undergo
“conformational selection” process from a collection of pre-existing ligand bound
states.4,40 Moreover, Boehr et al.4 proposed that ligands generally bind weakly populated
high energy receptor conformations to undergo an ensemble redistribution via population
shift leading to a net gain in free energy. Hence, the first step in traditional ensemble
docking constitutes the generation of ensemble receptor structures using any one of the
following techniques: MD simulations, Monte Carlo conformational search, normal mode
analysis and Simulated Annealing followed by sequential flexible ligand docking.
The high computational cost associated with traditional ensemble docking lead to
the development of hybrid ensemble docking techniques like 4D docking,41 FlexE,42 and
DOCK.43 The 4D docking protocol developed by Abagyan and co-workers41 is much
faster than traditional ensemble docking studies and their method reproduced
experimental binding modes in 77.3% of their test cases. Their 4D docking describes
protein flexibility as a 4th dimension relative to the ligand 3D space. Several 3D grids of
the receptors from the ensemble have been recomputed into a single 4D object (set of 4D
planes that describes the different protein conformations) using a superposition
algorithm. The implementation of a Monte Carlo sampling protocol, indicates that ligand
conformational changes are brought about in terms of torsional, rotational, and
translational movements from one 4D plane to another. Finally, all the poses within 1
kcal/mol of the lowest energy pose were retained for further analysis. Another advanced
program like FlexE42 uses a slight variation to 4D docking, in which the program
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combines multiple structure receptors, merging the rigid parts, and identifying the
flexible parts as dissimilar receptor conformations. During the incremental construction
of ligand, the ligand was sampled against various protein conformations to have the
maximum complementary interactions with flexible parts followed by score and rank.
1.6.5 Induced fit docking studies
Dissimilar from the lock and key theory, in induced fit theory ligand binds to the
receptor conformation by reshaping its active-site conforming to the ligand shape. This
process enhances the complementary interactions like electrostatics, van der Waals,
hydrogen bonding etc. It was recently shown that 85% of the PDB structures contain one
to three flexible active-site residues44 showing the high probability of induced fit effects.
Hence some of the popular programs like Induced fit docking (IFD) protocol 45,46 using
Glide/Prime would allow the users to select residues that are flexible based on B-factors
or based on RMSD’s from experimentally available structures. The Fleksy program47
identifies the residues automatically based on certain rules or the user can select them
manually. Most of the current docking schemes account for the induced fit effects using
a hybrid scheme. The processes generally include using softened potentials and
performing side chain sampling using rotamer libraries to include protein plasticity.
Further, these ligand conformations are docked into multiple receptor structures to
generate an ensemble of protein-ligand complexes. Later, these suboptimal poses undergo
partial refinement followed by redocking and final scoring of their respective binding
energies. The popular Prime/Glide IFD method is a hybrid model that is a flexible
receptor – flexible ligand docking protocol which accurately predicts the binding modes
by iterative combination of rigid docking (Glide)5 with protein structure prediction
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technique (Prime)48,49 to produce induced fit effects. IFD is computationally efficient, as
it performs side chain sampling in dihedral angle space while allowing minor backbone
movements through Prime energy minimization conferring full protein flexibility. This
technique is ideal for X-ray structures with no bound ligand (apo structure), in which the
amino acid residues protrude into the active-site leaving a closed active-site conformation
and causing rigid dockings to fail. The robustness and accuracy of the IFD methodology
has been originally validated on 21 pharmaceutically relevant protein targets by cross
docking studies.46 The IFD protocol successfully generated binding modes with ligand
RMSD ≤ 1.8 Å for 18 of the 21 test cases. Furthermore, the 21 test cases have an average
ligand RMSD of 1.4 Å when docked to the flexible receptors, while the traditional rigid
receptor docking gave an average RMSD of 5.5 Å.
SCARE50 is a similar induced fit docking program that scans for adjacent sidechains and replaces them with alanines creating a gapped pocket to reduce steric
hindrance, which is caused by docking bulky ligands into the active-site. Next, back
mutation of alanine paired residues to original residues is performed. Followed by
refinement and rescoring the ligands obtained a near native conformation (< 2Å RMSD)
for 80% of adjacent pairs using this method. Recently, an alternative CHARMM forcefield based IFD method was developed, that uses a similar multi stage induced-fit
docking process.51 The ChiFlex program was employed in the multi stage process to
sample the side chain conformations using a ChiRotor algorithm52 by selectively
removing less than 10 residues to create a gapped active-site pocket to generate an
ensemble of complexes. Later in the protocol, the favorable intermolecular forces are
maximized by identifying a hot spot for the ligand placement. CHARMM energy
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minimization calculations were performed to remove steric clashes resulting from side
chain reconstruction. And CHARMM based CDOCKER53 docking application is
employed to sample the ligand conformations using high temperature MD simulations
inside of the rigid receptor active-site to obtain the final intermolecular complexes. This
IFD method using 21 test cases obtained an RMSD < 2Å within the top five hits except
for one case.
1.6.6 Mutual adaptive coupled interaction studies
Accurate prediction of the dynamic nature of biological protein-ligand
interactions includes the understanding of simultaneous coupled forces between the
binding partners. This ultimately captures its snapshots of highly populated stable
conformations that represent true experimental stable structures. In addition, considering
only coupled interactions would restrict conformational degrees of freedom to relevant
binding conformations saving a lot of computational time. The ROSETTALIGAND26,54
is a popular docking method that simultaneously optimizes receptor side-chain, backbone
along with ligand flexibility degrees of freedom. This docking protocol models the
coupled interactions by using a Monte Carlo minimization procedure, where each ligand
from an ensemble of ligand conformations is translated and rotated along with
simultaneous optimization of receptor side-chains. The ligands are first placed effectively
in the active-site, based on shape complementary search. The side-chain optimization
starts with substitution of side-chains with rotamers from a backbone dependent rotamer
library,55 followed by quasi-Newton minimization. The end results are accepted based on
a Metropolis Criterion followed by a stringent gradient based minimization accounting
for ligand sampling along with receptor side-chain torsions and backbone flexibility. The
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first version of ROSETTALIGAND itself was reasonably good, a correlation co-efficient
of 0.63 was obtained when comparing between predicted binding energies to
experimental binding energies using a diverse set of 229 protein-ligand complexes.26
Moreover, the recent version of ROSSETTALIGAND was used to find the top scoring
ligand poses with RMSD < 2Å for 54/85 cases.54
Another traditional technique for capturing the coupled interactions of the proteinligand forces consists of MD simulations. MD simulation allows the biomolecular system
to evolve over time and are described by using Newton’s equation of motion. The
velocities and positions are tracked as a function of time to get the respective kinetic
energy and potential energy of the system. MD simulation aids in determining ensemble
averages and predicts ground state conformations of the protein-ligand complexes. Four
steps are involved in regular MD simulations, initializing the system with a specific
velocity and positions. Newtons equation of motion is used to compute the forces acting
on the system to determine its new positions. The system would reach equilibrium losing
the memory of initial conditions. The thermodynamic averages are calculated for
quantities of interest. Once the protein-ligand system is well equilibrated, the trajectory of
phase space should sample the regions of high probability distributed according to the
Botlzmann distribution. However, the small time steps in MD simulations prevent the
crossing of high energy barriers on potential energy surface (PES) causing inadequate
sampling. Further, despite the development of explicit solvent MD simulations for
binding mode predictions, success remains limited due to slow kinetics that form the
correct protein-ligand complexes (possibly needs few microseconds or longer
simulations) due to insufficient time to perform side-chain sampling and cross high
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energy barriers. Guida and co-workers56 have suggested that flexible ligand docking into
flexible active-site cannot be effectively performed using MD simulations due to large
energy barriers associated with ligand translational and rotational movements in the
PNP/9-deaza- 9-benzylguanine complex and have utilized torsional MC and low
frequency normal modes to account for protein side chain flexibility.57
1.7 Conclusion
A plethora of docking strategies exists that incorporate protein flexibilities in
ligand docking and are discussed in several review articles.3,11,25,40,58-60 A short overview
has been given for the currently existing flexible receptor docking protocols along with
their successful applications. Despite the successful development of flexible docking
protocols, a universal docking program that correctly predicts binding modes and
accurately rank orders binding affinities doesn’t exist. Every receptor target is unique
displaying various conformational degrees of freedom, ranging from bond vibration to
large scale domain motion. Hence, understanding the target receptor flexibility is of
prime importance to employ the correct flexible docking strategy ranging from moderate
plasticity like soft docking to fully flexible mutual adaptive interactions. Moreover, the
rigid docking programs in general are fairly accurate in predicting the binding affinities
for a congeneric series of ligands. In addition, the availability of structural information
for various potential inhibitors can help design hit molecules (SAR studies) by predicting
the binding modes and understanding their possible molecular interactions with the
receptor.

For our research studies in chapter 2, and 3 we used Schrodinger’s IFD

protocol that uses a combination of the Glide and Prime program. Glide has been well
validated49,50 while Glide / Prime has been shown to outperform other rigid and flexible
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receptor docking protocols.61 This technique is ideal for X-ray structures with no bound
ligand (apo structure). In such cases, amino acid side chains often protrude into the
active-site restricting conformational space, resulting in the failure of rigid docking
methods. Alternative approaches for incorporating flexible receptors into ligand docking
protocols exist; however, common procedures like explicit solvent MD simulations have
experienced limited success in predicting protein-ligand complexes.46 This limitation
results from several factors with two aspects particularly problematic. The first is the
necessity for accurate small molecule force fields.62-64 This is an active area of research,
but presently there is no comprehensive solution. A second problem exists if significant
active site reorganization is required for ligand binding. In this case, extensive
simulations (up to microseconds) may be required to cross the high energy barriers of
side-chain and/or backbone rearrangement. In contrast, IFD incorporates both side-chain,
and to some extent backbone flexibility in a more computationally efficient manner. This
has been extremely useful for a wide variety of computational biology studies.65-70 For
example, Celik et al.66 showed that IFD was able to prospectively predict the binding
mode of ligand neurotransmitter serotonin (5-HT) to the human serotonin transporter
(hSERT). Additionally, Barreca et al.71 predicted the binding mode and mechanism of
action of integrase strand transfer inhibitors in the target HIV-1 integrase. Hence, we
utilized this protocol in most of our research projects using a customized induced fit
docking (IFD) procedure to determine the binding modes of a series of HUA’s in both
hemoglobin and catalase Enzymes described below.
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Chapter 2. Unlocking the Binding and Reaction Mechanism of
Hydroxyurea Substrates as Biological Nitric Oxide Donors.
Note to the Reader
This chapter has been published as Vankayala, S. L.; Hargis, J. C.; Woodcock, H.
L. Unlocking the Binding and Reaction Mechanism of Hydroxyurea Substrates as
Biological Nitric Oxide Donors, J. Chem. Inf. Model. 2012, 52, 1288-1297. Copyright ©
2013 American Chemical Society. doi: 10.1021/ci300035c. PMID: 22519847
Author contributions. SLV and HLW designed the research; SLV performed research,
analyzed data and wrote the initial draft; HLW and JCH improvised the draft.
2.1 Abstract
Hydroxyurea is the only FDA approved treatment of sickle cell disease. It is
believed the primary mechanism of action is associated with the pharmacological
elevation of nitric oxide in the blood; however, the exact details of this are still unclear.
In the current work, we investigate the atomic level details of this process using a
combination of flexible-ligand / flexible-receptor virtual screening coupled with energetic
analysis that decomposes interaction energies. Utilizing these methods we were able to
elucidate the previously unknown substrate binding modes of a series of hydroxyurea
analogs to hemoglobin and the concomitant structural changes of the enzyme. We
identify a backbone carbonyl that forms a hydrogen bond with bound substrates. Our
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results are consistent with kinetic and EPR measurements of hydroxyurea-hemoglobin
reactions and a full mechanism is proposed that offers new insights into possibly
improving substrate binding and/or reactivity.
2.2 Introduction
Sickle cell disease (SCD) is an autosomal recessive disorder resulting from the
mutation of the 6th amino acid in the -globin gene changing from polar glutamic acid to
non-polar valine.72-74 Two biomedically relevant phenotypes of hemoglobin expressed are
normal adult hemoglobin (HbA) and its mutated SCD equivalent (HbS). More
specifically, upon deoxygenation mutated hemoglobin undergoes a conformational
change resulting in formation of long fiber-like polymers. Polymerization of HbS inside
of red blood cells distorts them into crescent shapes (i.e. sickled). Further, sickling causes
the extracellular exposure of protein epitopes and glycolipids that are normally found
inside the cell. Improperly exposed cellular components lead to increased adhesion of
sickled red blood resulting in stroke, acute organ damage, and death.75-77
Two current treatment options for SCD are administration of hydroxyurea (HU)
or red blood cell replacement.78,79 Hydroxyurea, the only FDA approved treatment for
SCD, involves the pharmacological elevation of nitric oxide (NO) and induction of fetal
hemoglobin (HbF).80 Watson et al. found that HbF ameliorates sickle cell severity.81 HbF
is primarily present in infants as an oxygen carrier protein during the last 7 months of
gestation through the first six months of a newborn’s life.82 HbF is a tetramer consisting
of two α and two γ globins (α2γ2), which accounts for approximately 1% of hemoglobin
in adults. HbF combines with oxygen more easily than adult hemoglobin due to the γ
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subunits that have more remote negative charge than its adult β counterpart.73 In SCD
patients, raising HbF levels lowers the cellular concentration of HbS and results in less
polymerization hence lower incidence of sickled red blood cells. HbF also serves as a
prognostic factor for sickle cell complications and pain crises.83 Although millions of
people have received this treatment, the detailed mechanism of action remains elusive.
It is thought that NO plays a key role in SCD treatment by producing smooth
muscle relaxation, vasodilation, and increasing regional blood flow to help prevent cell
adhesion to endothelial cells.84 Further, NO released from the endothelium activates the
NO/cGMP pathway85 that regulates expression of the γ globin gene along with
stimulation of HbF synthesis. During hydroxyurea administration, elevated levels of NO
metabolites, cGMP, and HbF are observed.86-88 Intrigued by in vivo conversion of
hydroxyurea to NO along with induction of HbF, research has focused on substrate
interaction with heme based proteins that catalyze redox processes. For example, OxyHemoglobin (OxyHb), Deoxy-Hemoglobin (DeoxyHb) and Met-Hemoglobin (MetHb)
have been shown to form Nitrosyl-Hemoglobin (HbNO), a source of NO.73,88-90
The structure of HbA, a tetramer assembly consisting of two α globins and two β
globins, has been studied extensively.91-97 Each of these subunits consists of a
hydrophobic pocket that strongly binds the prosthetic heme group.95 The heme group is
an octahedral coordinated system with ferrous iron having four coordinate bonds to
porphyrin nitrogens and a covalent bond with the proximal histidine (His87) below the
plane of the porphyrin ring. The sixth bond is a coordination bond with exogenous
ligands such as oxygen, carbon monoxide, or nitric oxide inducing planarity of the heme.
The immediate residues above the porphyrin ring plane constitute the distal pocket.
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Oxygen binds to HbA in a complex cooperative mechanism where the oxygen association
exhibits a sigmoidal curve.98 When OxyHb is auto-oxidized from the ferrous to ferric
form it gives MetHb and superoxide99 with the sixth coordinate position of MetHb either
empty or bound by a water molecule. In contrast, DeoxyHb is generated by
deoxygenation of OxyHb leaving a ferrous state iron (Figure 2-1).

Figure 2-1: Generic representation of various oxidation states of Iron that exist in human
adult hemoglobin.

In addition to its role in SCD therapy, hydroxyurea also acts as an S-phase
specific chemotherapeutic agent used primarily to treat cancer. Therefore, cytotoxicity
effects have been a major concern for patients undergoing treatment for SCD. This and
additional properties have lead to trepidation amongst physicians about long-term SCD
treatment with hydroxyurea,74 making the development of alternatives essential. In 2003,
King and co-workers88 designed a series of hydroxyurea analogs (HUA) depicted in
Figure 2-2 and examined their structure activity relationship using kinetic and EPR
spectroscopic techniques.
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Figure 2-2: List of hydroxyurea analogs tested by King and co-workers from their
structure activity relationship study.17 Defining various hydrogen atom representations:
A. hydrogen bonded to the non-hydroxyl nitrogen atom (HN′) B. hydrogen bonded to
hydroxyl nitrogen (HN) C. substituent groups bonded to the non-hydroxyl nitrogen atom
(X) D. hydroxyl hydrogen (HO) Hydroxyurea (1) serves as the archetype showing HN´,
HN, HO and X.
Rate constants for the reaction of OxyHb and hydroxyurea analogs forming
hydroxyurea nitroxide (HU-nitroxide) radicals have been previously determined.88,89 In
that work, a reaction rate increase of 25-80 times was observed for N-hydroxyurea
analogs compared to HU and it was suggested these would be superior nitric oxide
donors. King and co-workers88,90,100,101 conducted several spectroscopic studies and
proposed the mechanisms depicted in a series of redox reactions (Figure 2-3). These
illustrate hydroxyurea’s interaction with hemoglobin to produce NO. The in vitro reaction
of all hydroxyurea analogs except 2 and 3 produced HU-nitroxide radicals with OxyHb
through the abstraction of HO by bound oxygen (Ob) to form MetHb and hydrogen
peroxide. Additionally, all hydroxyurea analogs except 2, 3, and 7 were found to
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coordinate with MetHb to form the MetHb-HUA complex. The complexes eventually
decompose to form HU-nitroxide radical (2) analogs and DeoxyHb. Finally, NO is
formed by the decomposition of 2 and combines with DeoxyHb to form nitrosyl
hemoglobin (HbNO).102 The study concluded that effective NO release from hydroxyurea
analogs requires the formation of a low spin MetHb-HU complex. They concluded this
complex could only be formed if the necessary structural features were present: an
unsubstituted −NHOH group and a HN´ atom, henceforth analogs 2, 3, 4 and 7 could not
generate NO. They reasoned the HN´ requirement was steric in nature with the two ethyl
groups bonded to N responsible for analog 7’s inability to form the low spin MetHbHUA complex.88

OxyHb

MetHb

MetHb

MetHb-HU complex

DeoxyHb

MetHb
Figure 2-3: Generic reaction scheme presented by King and co-workers.17
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However, the role of HN´ in the complex formation was not addressed due to
unavailable structural information of hemoglobin with bound substrates. Moreover, there
was no discussion or comparison of the active sites of OxyHb and MetHb.
In the current work we utilize a customized induced fit docking (IFD) procedure
to determine the binding modes of a series of HUA’s in both OxyHb and MetHb. The
IFD45,46 protocol involves sampling dramatic side chain motions and minor backbone
movement to predict OxyHb-HUA and MetHb-HUA complex structures starting from the
apo conformation of OxyHb. Docking score decomposition analysis (i.e. Glide XP
descriptor) is used to probe the intermolecular interactions that govern binding and
stability. Sequence alignment and binding site similarity studies with α-HbA using
ProBiS103-105 and ClustalW106 reveal several conserved active site residues. This
information, in conjunction with available structural and biochemical data,95,101,107 is then
used to propose detailed reaction mechanisms and suggest new strategies for the
development of improved NO releasing substrates.
2.3 Methods
2.3.1 Protein and ligand/substrate preparation
X-ray crystal structure coordinates of apo OxyHb were obtained from the Protein
Data Bank [PDB: 2DN1].93 2DN1 is a high resolution, 1.25 Å, dimer with a hydrogen
bond between the distal histidine (His58) and Od, the distal oxygen atom (i.e. farther from
the central iron of the oxy-heme moiety), of both the α and β-subunits.108 The α subunit
was chosen because previous experimental and computational studies have shown it to
have higher affinity for ligands than its β counterpart.109-111 The impact module of the
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Schrödinger suite was used to predict the correct bond orders, add missing hydrogens,
and remove the co-crystallized water and toluene solvent molecules. The HIE protonation
state (protonated on N) was selected for His58 in OxyHb due to the aforementioned
hydrogen bonding.94,112,113 Subsequently, a minimization (Truncated Newton Conjugate
Gradient, TNCG) employing the OPLS-2005 force field with a constant dielectric of 2
was performed freezing the oxy-heme, proximal histidine (His87),107 and restraining (r =
2.5 Å, k = 105 kJ mol-1Å-2) the distance between the distal His58 hydrogen (HNε) and
Od.107,111,114 Using this structure, flexible docking studies described below were carried
out to generate OxyHb-HUA complexes. Subsequently, OxyHb-HUA structures were
manually processed to generate MetHb-HUA starting structures for flexible docking
studies, in which the bound oxygen molecule was removed, the Fe charge was converted
from +2 to +3, and the N of His58 was deprotonated. A TNCG minimization was
performed on MetHb-HUA using the same parameters applied to the OxyHb complex,
however, the distance restraint between HNε – Od was replaced by HN´ – OGly25 (i.e. closest
possible hydrogen bond). Schrödinger's LigPrep 2.3 was used to process the HUA
substrates and generate energy minimized molecular structures prior to docking.
2.3.2 Customized Induced Fit Docking
IFD is an accurate flexible receptor – flexible ligand docking protocol
which predicts binding modes by iterative combination of rigid docking (Glide)5 with
protein structure prediction (Prime).48,115 A customized IFD protocol was used to induce
protein flexibility into the apo structure of OxyHb with the same protocol used for
MetHb-HUA complexes. The following steps were undertaken with an in-house python
script developed to automate the process (Figure 2-4):
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1) Mutated flexible active site residues: The first step of this process involves mutating
all residues within 7 Å of the oxygen of oxy-heme to alanine. The distal and proximal
histidines, His58 and His87, respectively, were excluded from this process, as they were
deemed essential to the structure.
2) Initial Glide docking: Hydroxyurea analogs were docked into the OxyHb and MetHb
active sites, using Glide standard precision (Glide SP). Dockings were carried out with
vdW scaling of 0.5 for the ligand and 0.7 for both receptors, while HO was required to be
within 2.3 Å of the bound oxygen (Ob) in OxyHb88 and 2.5 Å from the deprotonated N
(His58) in MetHb. We requested 100 poses of partially optimized receptor-substrate
complexes to allow for extensive conformational examination.
3) Prime Refinement: Each Glide SP receptor-substrate output pose was refined by
prime, which performs side chain prediction by back mutating the alanine residues to
their initial amino acid. Back mutation was followed by minimization of the entire
receptor-substrate complex. This was done while retaining the original frozen atoms and
restraints (k = 200 kJ mol-1Å-2) from Glide SP. Again, in MetHb the HNε – Od distance
restraint was replaced by HN´ – OGly25 with the force constant for this interaction reduced
to 25 kJ mol-1Å-2. A TNCG minimization with full vdW radii for the receptor-substrate
complex was again performed using the OPLS 2005 all-atom force field with surface
generalized Born solvation energies. Following all minimizations, structures within a 40
kcal mol-1 energy window were retained for redocking (~50 – 100 structures).
4) IFD-XP redocking: Glide extra precision (Glide XP) redocking was performed with a
single positional restraint for both OxyHb and MetHb. The restraints required HO atoms
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to be within 2.5 Å of the oxygen Ob for OxyHb and His58 N for MetHb. XP descriptor
information for the best redocked (i.e. scored) ligand/substrates poses was analyzed.

Protein Preparation (Impact Minimization)

Mutate flexible active site residues within 7 Å
of Oxy143

Initial Glide SP Docking

Back mutation and Prime minimization with
pair wise restraints

Glide XP redocking

XP descriptors

Figure 2-4: The flowchart of IFD protocol followed to predict the binding modes of
hydroxyurea analogs in OxyHb and MetHb.
2.4 Results
Docking results of hydroxyurea analogs into OxyHb87,88,101,107 were obtained to
gain insight into the binding modes and redox reactions that produce NO in SCD
treatment. The binding modes were analyzed using the Glide XP scoring function, which
is broken down into individual interaction energies. These descriptors are viewable with
the “XP Visualizer” program in Maestro. The score includes favorable energy terms such
as the chemscore-lipophilic pair term (Lipophilic EvdW), hydrophobic enclosure
(PhobEn), hydrophobically packed hydrogen bonding (PhobEn HB), chemscore
hydrogen-bond interactions (HBond), electrostatic interaction (Electro), and low
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molecular weight (Low MW). The cumulative penalty term (Penalty) includes intraligand contacts, polar atom burial, amide torsion, and desolvation. The best-docked pose
for all hydroxyurea substrates in OxyHb was retained for the XP descriptor analysis
(Table 2-1). From the IFD results, Leu29, Phe33, Phe43, Phe46, Leu48, Val62 and Ala63
positions underwent substantial change where the RMSD was 0.5-4.36 Å when compared
to initial positions (Table 2-1A). All RMSD values were calculated with CHARMM116,117
as it was necessary to account for atom reordering that occurred during Prime’s back
mutation procedure.
The corresponding substrate representative binding modes are shown in Figure 25. All substrates except 7 (Figure 2-5b) show HO hydrogen bonded to the bound oxygen
atom (Ob), and their HN´ hydrogen bonded to the OGly25. 1 and 4 have similar binding
modes. Only 7 has a unique binding mode, whereas 5, 6 and 8 have congruent binding
modes.

Table 2-1: XP descriptor analysis derived from IFD-XP redocking of hydroxyurea
analogs into OxyHb, compared with the reported experimental rate constants.
Name

XP
score

1
4
5
6
7
8

-4.59
-4.42
-6.48
-5.36
-4.57
-7.35

Lipophil
-ic
EvdW
-0.45
-0.93
-3.10
-2.33
-2.27
-3.54

Phob
En

HBond

Electro

Low
MW

Pen
ality

Rate constant k1(min-1)
with OxyHb

0.00
0.00
-0.68
-0.25
0.00
0.00

-2.77
-2.50
-2.08
-1.89
-1.72
-3.13

-0.92
-0.49
-0.43
-0.40
-0.09
-0.46

-0.50
-0.50
-0.50
-0.50
-0.50
-0.50

0.05
0.01
0.31
0.01
0.01
0.27

7.54×10-4 ± 2.16×10-5
3.93×10-2 ± 1.68×10-3
6.24×10-2 ± 6.18×10-3
8.56×10-3 ± 1.87×10-4
2.26×10-3 ± 8.16×10-5
1.94×10-3 ± 5.50×10-4
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Table 2-1A: Summary of IFD studies of hydroxyurea analogs leading to
conformational movement of residues (RMSD values, Å) within 9 Å around O2 in
the active site of OxyHb compared to its apo structure
Residues
G25
A26
A28
L29
M32
F33
T39
F43
F46
L48
V55
H58
G59
K61
V62
A63
A65
L66
H87
L101
L105

HU1
0.35
0.31
0.55
1.74
1.23
1.52
1.67
0.37
0.51
2.53
0.69
0.47
0.78
0.91
1.94
0.87
0.29
0.74
0.25
0.28
0.55

HU4
0.26
0.20
0.58
1.94
0.66
4.28
1.51
1.30
0.36
0.49
0.28
1.24
0.29
0.63
1.10
0.33
0.29
0.48
0.25
0.42
0.46

HU5
0.93
0.98
0.83
3.44
0.67
4.36
0.79
0.91
0.75
0.71
1.56
0.98
0.65
0.72
0.82
1.11
0.43
0.68
0.25
0.50
0.43

HU6
1.62
1.60
1.48
2.35
1.33
1.24
0.54
0.54
0.32
2.00
1.35
0.93
1.23
0.61
1.88
1.50
0.57
1.48
0.25
0.81
0.92

HU7
0.83
0.68
0.75
1.70
0.46
0.99
0.48
0.54
0.56
2.63
0.72
0.62
0.91
1.01
1.72
1.39
0.63
2.44
0.25
1.36
1.45

HU8
0.37
1.24
0.77
3.53
0.50
1.52
0.45
0.24
0.52
2.16
1.41
0.59
0.72
0.78
2.12
1.84
0.56
0.76
0.25
0.16
0.32

IFD was also performed for MetHb with the restraints described in the methods
section. The XP descriptor analysis results are presented in Table 2-2 and Figure 2-6
illustrates predicted binding poses of 1, 7, and 8. IFD caused the following residues;
Leu29, Phe33, Phe43, Phe46, Leu48, Val62 and Leu105, to undergo substantial change:
RMSD 0.6-3.92 Å compared to their respective OxyHb complexes (Table 2-2A). Our
results show that 7 has the smallest hydrogen bonding contribution in MetHb due to the
lack of a hydrogen bond between HN´ and OGly25. Also, 5 and 8 have similar binding
modes with significant hydrophobic stabilization.
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Figure 2-5: Predicted binding modes of the hydroxyurea analogs, 1 and 7 in OxyHb.
Carbons of heme and ligands are colored green, oxygen red, nitrogen blue, sulfur yellow,
hydrogen grey and iron light blue. Hydrogen bonding interactions are shown as black
dashed lines and the active site loop is highlighted as a yellow ribbon.
Table 2-2: XP descriptor analysis of all hydroxyurea analogs obtained from IFD-XP
redocking in MetHb.
Name
1
4
5
6
7
8

a)

XP
score
-3.27
-3.31
-7.80
-3.93
-4.13
-6.03

Lipophilic
EvdW
-0.56
-0.95
-2.76
-2.16
-2.14
-3.42

G25

Phob
En
0.00
0.00
-0.78
0.00
0.00
0.00

b)

PhobEn
HB
0.00
0.00
-1.50
0.00
0.00
-1.50

HBond

Electro

-1.76
-1.62
-1.62
-1.61
-1.33
-1.35

-0.56
-0.30
-0.78
-0.38
-0.33
-0.24

c)

G25

A28

Low Penality
MW
-0.50
0.10
-0.50
0.07
-0.50
0.16
-0.50
0.72
-0.50
0.17
-0.50
0.99

G25

L105
L129

L110

H58

H58

V62

H58
L110

L110

Figure 2-6: IFD structures for predicted binding modes of the hydroxyurea analogs, 1, 7
and 8 in MetHb are depicted in 6a, 6b and 6c, respectively.
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2.5 Discussion
The current work seeks molecular level insight into the binding modes and
reactions for a series of hydroxyurea analogs in OxyHb and MetHb. Until now, details of
these processes have remained elusive, largely due to the lack of co-crystallized structural
information. Current results combined with previous structural91,97,101 and biochemical
information87,88,101 allow for the first prediction of HU (and analogs) binding and
subsequent reaction mechanism.
Table 2-2A: Summary of IFD studies of hydroxyurea analogs leading to
conformational movement of residues (RMSD values, Å) in MetHb compared to their
respective OxyHb structures. For comparison we listed conformational movements of the
same residues shown in OxyHb.
Residues
G25
A26
A28
L29
M32
F33
T39
F43
F46
L48
V55
H58
G59
K61
V62
A63
A65
L66
H87
L101
L105

HU1
0.18
0.17
0.16
0.34
0.36
0.74
0.15
3.21
1.41
0.83
0.20
0.13
0.54
1.16
1.51
0.36
0.43
0.65
0.11
0.15
1.66

HU4
0.43
0.39
0.35
1.27
1.11
0.13
0.34
2.92
2.04
0.76
0.16
0.15
0.32
0.23
1.19
0.08
0.09
0.11
0.39
0.55
1.59

HU5
1.21
1.13
1.10
2.90
1.49
1.02
0.31
3.92
2.63
2.00
1.53
0.28
0.21
0.71
0.20
0.28
0.10
0.17
0.19
0.58
1.79
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HU6
0.52
0.49
0.51
1.43
0.59
3.18
0.66
2.70
3.57
1.92
1.63
0.06
0.31
1.54
2.58
0.67
1.14
0.72
0.36
0.41
1.64

HU7
0.18
0.10
0.08
1.18
1.11
0.36
0.13
2.82
1.46
0.62
0.32
0.00
0.08
0.00
1.31
0.08
0.08
0.12
0.20
1.41
1.19

HU
0.48
8
1.27
0.35
2.88
1.13
3.96
0.55
2.17
1.31
2.33
1.56
0.14
0.45
0.36
1.43
0.49
0.53
2.07
0.33
0.85
1.90

Figure 2-7: Proposed mechanism of action between hydroxyurea analogs and adult
hemoglobin a) Reaction scheme 1 demonstrates interaction of 1 with OxyHb to give
hydroxyurea nitroxide radical (2). b) Reaction scheme 2 shows the possible mechanistic
interactions between 1/2 and MetHb to produce DeoxyHb and 2.
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The putative narrow OxyHb substrate binding site consists of several hydrophobic
residues, oxy-heme, and His58; an imidazole functional group that acts as a ligand gate
for entry into the OxyHb active-site.112 His58 also acts as a proton donor in the proposed
mechanism (Figure 2-7a). In this reaction, the nature of Fe-O2 bonding exists in
accordance with the Weiss bonding model,95,107,114 in which a single electron transfer
from Heme-FeII to Ob leads to Heme-FeIII-O2- complex.95,118
Soon after the radical localizes on the bound oxygen, we hypothesize it will be
transferred to the hydroxyurea substrates by abstracting HO, leaving 2 (Figure 2-7a).
Subsequently, negative charge generated on Od will abstract hydrogen from His58
forming H2O2. Since the first step involves HO abstraction in all the hydroxyurea
substrates, we performed IFD studies with an explicit positional restraint enforcing the
HO to be within 2.5 Å of the Ob. The OxyHb studies revealed that all analogs fit well in
the active site that is surrounded by various hydrophobic residues. Leu29, Phe33 and
Val62 experienced the greatest active site conformational rearrangement due to
accommodation of substrates during the IFD procedure (Table 2-1A).
Figure 2-5 illustrates that all hydroxyurea analogs preferentially form a hydrogen
bond to OGly25 except for 7, due to the absence of HN´. Hence, the total XP hydrogen
bonding score for 7 (Phob En HB + Hbond) derived from IFD has the smallest
contribution to the total Glide score. The hydrophobic substrate groups, phenyl, n-butyl,
and methoxyphenyl bonded to N of 5, 6 and 8, respectively, occupy a well-defined
hydrophobic cavity in OxyHb created by Leu29, Met32, Phe43, Phe46, Leu48, Val55 and
His58. These additional hydrophobic interactions (Lipophilic EvdW + PhobEn) increased
stabilization by 2.5-3.8 kcal/mol. The enhanced hydrophobic contribution of 5 and 8
34

compared to 6 can be attributed to partial π-stacking between the side chain of His58 and
their corresponding phenyl and methoxyphenyl substituents; clearly seen in Figure 2-8.
Substrate 8 has even better binding affinity to OxyHb than 5 due to the additional
hydrophobic contribution from the methoxy group with Leu29, Phe33, Phe46 and Val55
(Figure 2-5). The tighter binding may be correlated to 8 having a smaller rate constant
than 5 when reacting with OxyHb (Table 2-1).88

F33

L29

5

H58
Od
Ob

Figure 2-8: Comparison of the induced fit conformation of OxyHb with 5 (in dark green)
and apo structure of OxyHb (in yellow). All hydroxyurea analogs in general induce
receptor flexibility by generating a Leu29 flip, which further moves away Phe33.
Custom IFD was undertaken based on the proposed mechanism in Figure 2-7b.
Results showed that 7 has less hydrogen bonding stabilization in MetHb compared to
OxyHb. This stabilization is hypothesized to be necessary to retain the substrate
radicals/anion in MetHb (Figure 2-7b) and suggest an explanation as to why 7 does not
form a low-spin MetHb-HUA complex,88 a pre-requisite in the formation of HbNO. A
closer inspection of docking scores and XP descriptors reveals only modest differences in
stabilizations and penalties comparing 7-OxyHb and 7-MetHb. This suggests that steric
clashes, which have been previously hypothesized as the cause of 7 not producing NO are
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not likely responsible. Again, this supports our hypothesis that the lack of hydrogen
bonding to OGly25 is the more likely explanation.
To further support our hypothesis, that steric repulsion is not the cause of 7’s lack
of reaction, we have modified analog 6 when bound to MetHb by replacing the hydrogen
bound to N with a methyl group constructing 6a. This complex “should” represent a
more sterically hindered environment. The protein complex, 6a, was minimized until the
RMSD reached a maximum cutoff of 0.30 Å from the explicit coordinate geometry of 6
using the TNCG algorithm and later the ligand was scored in place by the Glide XP
docking algorithm. XP descriptors were obtained to compare 6 and 6a (Table 2-3). As
anticipated, the Δhydrogen bond difference was 0.92 kcal/mol, indicating a significant
loss of hydrogen bonding stability for 6a. The methyl bonded to the N atom improved
the lipophilic vdW contribution by 0.1 kcal/mol and surprisingly reduced the penalties
from 0.72 to 0.16 kcal/mol. These results again demonstrate the importance of the HN´
atom for hydrogen bonding and shows that adequate space is available to accommodate
additional substituents on the N atom.
Table 2-3: XP descriptor analysis of 6, 6a and 7 obtained from IFD-XP docking in
MetHb.
Name Docking Hbond Lipophilic HBond Electro Low Penalties
score
CO
EvdW
MW
Res
6

-3.93

Gly 25

-2.16

-1.61

-0.38

-0.50 0.72

6a
7

-3.62
-4.13

None
None

-2.25
-2.14

-0.77
-1.33

-0.26
-0.33

-0.50 0.16
-0.50 0.17
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The XP descriptor analysis explains the observed difference in the binding modes
of 5 and 8 in OxyHb and MetHb (Figures 2-5 and 2-6, respectively). The different
conformation of 5 and 8 in MetHb is attributed to the loss of a hydrogen bond interaction
with Ob that is required to stabilize the protein-substrate complex. Therefore hydrophobic
substrate groups, phenyl and methoxy phenyl on the N atom of 5 and 8, respectively,
occupy a different well-defined hydrophobic cavity created by Gly25, Ala28, Val62,
Leu101, Ser102, Leu105 and Leu129 in MetHb (Figure 2-6c). We also observe contrary
binding affinities in the case of MetHb, as shown by 5 having a lower docking score than
8 (Table 2-2). We attribute this to unfavorable steric interactions by the methoxy
subgroup within the hydrophobic cavity that lead to high penalties. Hence, we propose
hydroxyurea substrate design for effective NO release should involve optimizing the
interactions between hydrophobic substituent (X) and hydrophobic residues in the active
site of OxyHb and MetHb while ensuring that there is a hydrogen bond between the HN´
atom and OGly25.
To gain further insight into the importance of Gly25 and the aforementioned
hydrophobic residues, we examined active site conservation using a protein binding site
detection tool (ProBiS)103-105 along with ClustalW.106 ProBiS uses a database of 29,412
non-redundant PDBs to represent structural diversity. This group is searched using a
novel algorithm based on the clique approach119 that effectively identifies binding site
topologies with similar geometric and physicochemical properties to the query protein.
Using the adult hemoglobin HbA [PDB ID : 2DN1 – A chain] as the query protein
ProBiS yielded 302 protein structures with similar binding site topologies. The proteins
with Z-scores (statistical measure of protein similarity) > 2 were analyzed with additional
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similarity calculated using local structural alignment. The local structural similarity Zscores along with the Pfam entities are depicted in Appendix (Figure A-2).
ProBiS’s structure based sequence alignment results showed the most conserved
active site residues to be: Phe43, His58, Val62, Leu83, His87, Phe98, Leu100, Leu101,
and most conserved substituted residues to be: Gly25, Leu29, and Phe46. Conservation is
present across all 302 non-redundant structures with human globin proteins like
Cytoglobin, Myoglobin, β-HbA, δ-HbA, and Neuroglobin having similar binding sites to
α-HbA and high sequence identity. Sequence alignment using these six proteins was
subsequently carried out with ClustalW. Results revealed Gly25, Phe43, His58, Val62,
and His87 to be the most conserved residues with Phe46, Leu83, Phe98, Leu100, and
Leu101 being the most conserved substituted residues (Figure 2-9 and Figure A-3). The
identification of conserved Gly25 and important hydrophobic residues provides further
evidence supporting our above recommendations.
CLUSTAL 2.1 multiple sequence alignment
2DN1_A|SEQUENCE
2DN1_B|SEQUENCE
1SHR_B|SEQUENCE
2DC3_B|SEQUENCE
3RGK_A|SEQUENCE
1OJ6_D|SEQUENCE

---------------VLSPADKTNVKAAWGKVGAHAGEYGAEALERMFLSFPTTK
--------------VHLTPEEKSAVTALWGKV--NVDEVGGEALGRLLVVYPWTQ
--------------VHLTPEEKTAVNALWGKV--NVDAVGGEALGRLLVVYPWTQ
KVPGEMEIERRERSEELSEAERKAVQAMWARLYANCEDVGVAILVRFFVNFPSAK
---------------GLSDGEWQLVLNVWGKVEADIPGHGQEVLIRLFKGHPETL
----------------MERPEPELIRQSWRAVSRSPLEHGTVLFARLFALEPDLL
:
:
:
* :
*
: *::
*

40
39
39
60
40
39

Figure 2-9: Mutiple sequence alignment studies of human globin chains includes α-Hb,
δ-Hb, β-Hb, Cytoglobin, Myoglobin and Human Neuroglobin using Clustal W2 in which
2DN1-A is used as the query protein. And the various legends given below the sequences
represent "*" residues are identical, ":" observed conserved substitutions, "." observed
semi-conserved substitutions. The amino acid residues are colored according to their
physio- chemical properties in which red implies small hydrophobic (AFILMPVWY);
blue implies acidic (DE); purple implies basic (HKR) and green implies with hydroxyls
and amines and basic too (CGHNQSTY)
As previously mentioned, King and co-workers observed a large rate increase for
5 and 8 as compared to 1. They attributed this effect to the presence of aromatic
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substituents and their ability to stabilize the initially formed nitroxide radical (similar to
2).88 There is some controversy surrounding this prediction as Rohrman and Mazziotti
computationally examined the radical stabilization of King’s HU derivatives.89 They
predicted the enhanced rate of 5 was most likely due to transition state stabilization as it
had a very small radical stabilization, in apparent contrast with King’s hypothesis.
Rohrman et al. also suggested that longer alkyl chains at the X position should improve
substrates, however, they were unable to confirm these were sterically allowed in the
OxyHb active site. From the large RMSD’s (0.5-4.36 Å) induced by substrate docking in
OxyHb, we conclude the hydrophobic pocket is a possible source of the previously
hypothesized transition state stabilization. Additionally, the newly predicted HO – OGly
hydrogen bond helps to further clarify the observed reactivity and positions itself as
another possible source of transition state stabilization.
Although the exact mechanism of radical production from hydroxyurea analogs
with MetHb is unclear, our docking studies give insight into likely reactions. Examining
the importance of HN´ binding contributions to the total binding affinity lead us to explore
the low-spin MetHb-HUA complex formation. This yields three possible hypotheses A,
B, and C for MetHb reaction scheme 2. Hypothesis A entails a new substrate molecule
entering MetHb by replacing the existing substrate radical from reaction 7a as proposed
by King and co-workers.88 However, it is unclear as to what happens to the radical once it
leaves the active site as it will most likely get quenched and not be retained for the third
reaction (Figure 2-3). In hypothesis B, the substrate radical will be retained in the active
site through the stable hydrogen bonding interaction between HN´ and OGly25.
Furthermore, adequate data in the literature120-122 supports the plausibility of hypothesis
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B, in which various electron transfer reactions occur commonly either in solvent media or
intra- or inter-tetramer subunits of hemoglobin. The complex array of hemoglobin
electron transfer mechanisms indicates that an electron can easily be transferred to the
hydroxyurea nitroxide radical to form the hydroxyurea nitroxide anion. The anion would
then coordinate to the ferric iron of MetHb to form a low-spin MetHb-HUA complex.
Hypothesis C is similar in mechanistic detail to hypothesis A, except that the
hydroxyurea analog substrate is reformed from the interaction of the substrate radical and
a hydrogen radical abstracted from an active site water molecule. Because the active site
is at the surface of hemoglobin subunits, water should be available to facilitate this
mechanism. After scrutinizing hypotheses A, B, and C, it seems likely that either the
hydroxyurea anion substrate or the hydroxyurea substrate radical will be retained in the
active site by the hydrogen bond to OGly25 and react to form the low spin MetHb-HUA
complex.
2.6 Conclusion
Sickle cell anemia is an inherited disease that causes sickling of red blood cells.
There is a growing need for drugs that can effectively release NO to ease the intense pain
and also elevate HbF levels that possess better oxygen affinity than HbA. Unfortunately,
the discovery of novel drug substrates that produce effective NO release has been
hindered by the lack of structural information focusing on the interaction between Hb and
hydroxyurea, the only FDA approved SCD treatment. In the current work, we employed
an effective docking protocol to obtain the first bioactive 3D models of OxyHb and
MetHb with a congeneric series of hydroxyurea analogs. Furthermore, we proposed
reaction mechanisms (Figure 2-7a and 2-7b) based on combined information obtained via
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binding modes and previous biochemical data. IFD results and the proposed mechanisms
offer new insights into key intermolecular interactions that may be exploited during
rational substrate/drug design.
The current work elucidates the importance of the HN´ atom and its contribution as
a vital stabilizing interaction. This sheds new light onto the previously observed HUA
HN´ requirement.88 XP descriptor analysis also yields insight into key structural
requirements for small molecules interacting with OxyHb and MetHb. Substrates having
aromatic functional groups are shown to have better binding affinity than other
hydroxyurea analogs in Hb due to their favorable van der Waals, π-stacking, and
hydrophobically packed hydrogen bonding energy5 contributions. Our observations show
that to achieve better substrate design for effective NO release, it is important to consider
the exploitation of this key HN´ bonding interaction with OGly25, along with maximizing
the hydrophobic interactions within the deep hydrophobic pocket of hemoglobin.
Furthermore, from observed binding site similarities and high % sequence identities to αHbA, we hypothesize that hydroxyurea analogs may undergo similar biochemical
interactions across the human globin family of proteins. In fact, other heme-based
enzymes, for example Catalase,123,124 have already been identified as hydroxyurea targets.
In the future, we plan to explore the binding modes and reaction kinetics of these
additional redox active enzymes.
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Chapter 3: How Does Catalase Release Nitric Oxide? A
Computational Structure Activity Relationship Study
3.1 Abstract
Hydroxyurea is the only FDA approved medication for treating sickle cell
anemia in adults. The primary mechanism of action induces pharmacological
elevation of nitric oxide (NO) levels and leads to propagation of fetal hemoglobin.
Despite this overall understanding, specific details about the hydroxyurea (HU)
interaction with various heme based enzymes to produce NO remains unknown.
Recent experimental studies indicate the interaction of HU with human catalase
compound I produces NO. Presently, we combine ﬂexible receptor-ﬂexible substrate
induced fit docking (IFD) with energy decomposition analyses to examine the atomic
level details of a key step in the clinical conversion of HU to NO. Substrate binding
modes of seven HU analogs with catalase compound I were investigated to determine
the essential properties necessary for effective NO release. Two major binding poses
provides insight into possible reaction mechanisms which would result in NO
production. Further results show that, anion/radical intermediates produced as part of
these mechanisms would be stabilized by hydrogen bonding interactions from distal
residues His75, Asn148, Gln168, and oxoferryl-heme. These details will contribute to
the design of superior NO releasing agents, hence furthering drug design efforts
targeting sickle cell disease.
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3.2 Introduction
Sickle cell disease (SCD), an inherited monogenic disorder, results from the
mutation of the 6th amino acid in the -globin gene changing from the polar amino acid glutamic
acid to the non-polar residue valine.74 This mutation forms defective, sickled, hemoglobin
(HbS). Upon deoxygenation, HbS undergoes polymerization into long fibrils that
ultimately results in "sickled" red blood cells. Symptoms of SCD are intense pain,
microvascular vaso-occlusion, acute chest syndrome, strokes, severe multi-organ damage,
and even death.75,125,126 In 1998, the FDA approved hydroxyurea (HU) as a SCD
treatment127 and it remains the only remedy for severe cases.128 HU elevates nitric oxide
(NO) levels subsequently inducing fetal hemoglobin (HbF) production, which mitigates
sickle cell severity. HU augments HbF synthesis by raising -globin gene expression through
the activation of NO dependent soluble guanylyl cyclase (sGC) pathway85 in the human erythroid
progenitor cells. Further, NO generated from HU assists in maintaining normal blood
pressure, smoothening muscles, producing relaxation, and improving blood ﬂow to assist
patients with intense pain resulting from inﬂammation. Increased NO bioavailability also
improves red cell rheological properties and endothelial cell interactions. Moreover, HU
ameliorates antioxidant defense by decreasing lipid peroxidation levels by at least 30 due
to its contribution to higher catalase activity in SCD patients.129 SCD patients undergoing
HU therapy are known to produce various intermediates like C-nitroso formamide,
nitroxyl, nitric oxide, nitrates, and nitrites, which have numerous human physiological
effects.130
A recent study by King and co-workers123 showed that HU interacts with oxy and
deoxyHb resulting in slow NO production rates. This did not correlate with the
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observed increase in NO concentrations in patients undergoing HU therapy. The
discrepancy can be attributed to the interaction of HU competing with other heme
based enzymes88,101,123,124,131 such as catalase, human globins, and peroxidases that are also
known to produce NO. Elucidation of the molecular level interactions between HU and
each of these heme-based enzymes is critical to understanding NO metabolite
concentrations in patients undergoing HU therapy. Specifically, hydroxyurea analogs
(HUA, Figure 3-1) previously established to be a good diversity set through interaction
with hemoglobin,88 will be used for a computational structure activity relationship
(SAR) study with catalase.

Figure 3-1: Hydroxyurea analogs tested for their structure activity relationship by King
and co-workers in hemoglobin. The specific nomenclature used for diferent hydrogen and
nitrogen atoms is: nonhydroxyl nitrogen atom (N ), nitrogen attached to hydroxyl moiety
(NO), hydrogen atom bonded to N' atom (HN′), hydrogen bonded to N O atom (HN),
hydroxyl hydrogen as (HO), and substituent alkyl/phenyl groups bonded to the
nonhydroxyl nitrogen atom (X). We used hydroxyurea as a generic model to define the
various groups.
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Catalase enzymes are typically classified into three sub-types: mono-functional,
bifunctional catalase peroxidases, and pseudo catalases.132 Mono-functional catalases,
known as mammal catalases, are commonly present in animals. Their quaternary
structures are similar across organisms and are generally present as a tetramer with four
equal subunits consisting of a hydrophobic pocket that strongly binds heme prosthetic
groups. The catalase heme group exists as a pentavalent coordinated system with ferric
iron having four coordinate bonds to porphyrin nitrogens while the fifth bond is to the
proximal tyrosine. Compared to most other enzymes, catalases are more resistant to pH
change and thermal denaturation due to their stable tetrameric interactions. 133 They are
also known to play an important role in soothing inﬂammation, mutagenesis, and
prevention of apoptosis.132 Catalases also promote higher antioxidant defense mechanisms
against reactive oxygen species (ROS);129,134 reducing oxidative stress, inﬂammatory
response, and membrane lipid peroxidation levels in SCD patients undergoing HU therapy.

Catalase is primarily known for combating ROS such as hydrogen peroxide (H2O2).
Ferric catalase protects hemoglobin by dissociating two H2O2 molecules sequentially in
normal human erythrocytes into water and oxygen molecules.132 The reaction cycle135
III

begins with high spin ferric (Fe ) heme interacting with H2O2 to form an oxoferryl
IV

+•

porphyrin cation radical (O=Fe -Por ), also known as compound I (CpdI). The
second H2O2 molecule reduces CpdI to its native resting state enzyme.
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Figure 3-2: Proposed reaction mechanism by Fita and Rossmann,136 for H2O2 interaction
with catalase CpdI. Reaction scheme involving His mediated mechanism of action and
reaction scheme describing direct mechanism of action.

Two possible mechanisms have been proposed for the H2O2-catalase CpdI reduction:
a His mediated mechanism and a direct mechanism. The His mediated mechanism,
proposed by Fita and Rossmann,136 is comprised of sequential hydrogen transfer to CpdI
with the distal His playing a catalytic role. This differs from the direct mechanism137
where the hydrogen atoms are successively transferred from H2O2 to the oxoferryl group
in the active site with His only playing an intermolecular role (Figure 3-2). The direct
mechanism is proposed by Kato and co-workers.
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Figure 3-3: Generic representation of catalase mediated NO production from
hydroxyurea by King and co-workers. The reaction step highlighted in red box shows the
intermediacy of C-nitroso formamide, a prerequisite precursor for NO formation.

King and co-workers have undertaken extensive EPR spectroscopic studies to explore
a similar reaction profile comprising of catalase in a series of reactions with HU to
produce NO.123,124,130 The catalase mediated NO reaction begins with the production of
CpdI, similar in mechanism to H2O2. CpdI interacts with HU to produce C-nitroso
formamide followed by the formation of nitroxyl (HNO) upon hydrolysis. Subsequently
HNO interacts with native ferric catalase to generate a ferrous NO-catalase complex
(Figure 3-3), which serves as a source of NO. The released NO was judged by
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Oxyhemoglobin assay and EPR spectroscopic trapping studies.123 However, the detailed
mechanism of action remains unclear due to the lack of a 3D bioactive crystal structure,
necessary to probe the atomistic interactions between human catalase and HU. Herein we
seek a greater understanding of the atomistic interactions between catalase CpdI and the
hydroxyurea analog diversity set by a combination of ﬂexible receptor-ﬂexible substrate
induced fit docking (IFD), bioinformatics, and quantum mechanics (QM) studies.
3.3 Computational Details
X-ray crystal structure coordinates of catalase were obtained from the protein data
bank [PDB: 1DGG].1381DGG is a high resolution, 1.5 Å tetramer containing NADPHs
and heme prosthetic groups and bound cyanide. The prosthetic heme iron exists in the
hexa coordinate state. The NADPH region is hydrated, whereas the immediate active site
and -barrel regions are devoid of structural waters. Chain A of PDB: 1DGG was used and
the cyanide group was manually back mutated to an oxygen atom along with
incrementing the charge on iron to +4 to replicate CpdI. The IMPACT molecular
mechanics program139 was used to correct bond orders, add missing hydrogens, and
remove co-crystallized water molecules not present in the active site. The histidine
protonation state HSD (protonated on N1 only) was selected for His75 corresponding to
the His mediated Fita-Rossmann mechanism.136 A Truncated Newton Conjugate
Gradient (TNCG) minimization was performed using the OPLS-2005 force field. The
oxoferryl-heme was frozen in a constant dielectric of 2. All substrate structure atomic
coordinates were built and minimized using Schrodingers LigPrep 2.3140 module before
preliminary docking investigations.
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Enzyme ﬂexibility is a key component in determining receptor/substrate
recognitions. We used ﬂexible receptor-ﬂexible ligand docking, also known as
IFD45,46 to characterize conformational changes in catalase CpdI upon HUA binding.
The IFD protocol uses a combination of rigid docking (GlideXP) with protein
structure prediction (Prime).46This methodology has been well validated and
successfully applied to various biological problems including loop predictions,115,141
homology modeling,70 fragment based docking,69 and enrichment studies.68,142 The
various steps implemented in sequential order during the IFD protocol are described
below:
1) Active site residues mutated to Ala: Temporary mutation of all side chains residues
within 9 Å of the oxoferryl oxygen to Ala that impede ligand access into active site.
The distal His75 was excluded from this process as it is essential to the structure's
integrity.
2) GlideSP docking: Rigid GlideSP docking of HUAs was performed against the
mutated catalase CpdI structure with softened van der Waals potential to reduce
sterical clashes and increased Coulomb-vdW non bonded interaction energy cutof
value to 100 kcal mol-1 to generate more poses. Further, dockings were performed by
scaling the vdW radii by a factor of 0.5 for the ligand and 0.7 for the receptor to
generate an initial ensemble of docked poses. 300 poses of partially optimized
receptor-substrate complexes were requested.
3) Protein refinement/minimization: The GlideSP docked complexes were refined by
prime's structure prediction tool using the OPLS-2005 force field and generalized
Born solvation model.48,49,143 The alanine residues were back-mutated to their initial
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amino acids. In prime refinement mode, IFD uses a three step procedure to sample
side chain conformations and predict ligand-residue orientations. a) Rotamer libraries
developed by Xiang and Honig143 were used to sample the side chain conformations.
All side chains within 9Å of the bound oxygen in the oxoferryl group were back
mutated simultaneously in a random rotamer state. b) Each side chain is then
minimized sequentially using the single side chain procedure. This protocol involves
minimization of a single side chain (< 0.001 kcal mol-1

rms gradient) in

cartesian space by freezing all other residues. The procedure is repeated for all
residues until convergence is achieved. c) Finally, a TNCG minimization with full
vdW radii was performed to resolve any remaining sterical clashes. In prime
minimization mode, the side chain sampling is turned of (step 3a). That is, the
rotamer library sampling is not performed and sequential side chain minimization is
carried out (step 3b, 3c).
4) GlideXP redocking: The substrates within a 40 kcal mol-1 energy window of the
lowest energy structure from the prime refinement step were redocked into the
induced fit structures. GlideXP was performed with full vdW scaling for both the
receptor and substrate. 500 poses were requested for the GlideXP redocking and
ranked based on the GlideXP score. XP descriptors were generated by fragmenting
the composite scoring function into various interaction energies to analyze the docked
poses.
The interaction energies are described by GlideXP terms. The reward term
includes: HBond, a generic chemscore hydrogen bonding pair term;16 PhobEn Hb, a
hydrogen bond in protein hydrophobic enclosure; PhobEn, a hydrophobic enclosure
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term; LipophilicEvdW, a chemscore-lipophilic pair term; Electro, an electrostatic
contribution; Sitemap, complementary non hydrogen bonding interactions; and
LowMW, a reward for having lower molecular weight. The penalty term consists of:
RotPenal, a rotatable penalty for constricting ﬂexible ligands, and XP Penalties, a
collective combination of intraligand contact, polar atom burial, amide torsion, and
desolvation. The IFD protocol successfully generated binding modes causing Val74,
Val116, Phe153, Phe161, Ile165, and Gln168 to undergo substantial side chain
motion

(rmsd's

>1Å)

in

comparison

to

their

apo

structures.

We

used

CHARMM117,144,145 to compute side chain rmsds accounting for the two fold
symmetry of the phenylalanine side-chains in addition to the atom renumbering that
took place in the prime back-mutation step.
3 . 4 Results and Discussion
The aforementioned HUAs were initially tested by King and co-workers88 for their
efficacy to produce NO while interacting with adult human hemoglobin. Analogs 1, 5, 6,
and 8 produce NO due to the presence of the -NHOH group and the HN′ used to stabilize
the radical intermediates by a hydrogen bond to Gly25.146 However, this difers from the
present case of catalase CpdI wherein these analogs can only form the C-nitroso
formamide intermediates to produce NO. And currently, we do not have x-ray crystal
structures to comprehend the key interactions between HUAs and catalase CpdI to form
the necessary C- nitroso formamide intermediates, hindering HUA substrate design
process. Here we explore catalase CpdI substrate specificity with the same HU derivatives
and predict reaction profiles for releasing NO. Further, IFD was coupled with the XP
descriptor analysis to probe interaction energies. The docking protocol was validated by
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comparing with a QM/MM optimized structure previously generated by Alfonso- Prieto
et al.137 that contains a intermolecular hydrogen bonding array between H2O2 and catalase
CpdI (Figure 3-4). The H2O2 pose generated using our IFD protocol matched that of the
QM/MM optimized structure along with its networked intermolecular hydrogen bonds
between -NH2 of Asn148 as a hydrogen bond donor interacting with the lone pair of the
adjacent hydroxyl group from the H2O2. Further, the second hydroxyl group serves as the
hydrogen bond donor for the N of His75.

Figure 3-4: Inter-molecular hydrogen bonding network observed for the H2O2 docking
orientation in catalase CpdI active site. Protein carbons are colored in cyan; CpdI
carbons, yellow-green; oxygens, red; nitrogens, blue; hydrogens, white; and iron, light
blue. Dotted yellow lines represent the hydrogen bonding interactions and the ribbons
have red for -helices and cyan for --sheets.
The IFD protocol produced an ensemble of induced-fit catalase CpdI complexes,
which were clustered into five groups for each HUA from the diversity set. Two
predominant pose conformations were obtained for most HUAs and were categorized as
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pose A and pose B orientations. The top scoring poses from each cluster were used for
further analysis. Pose A and Pose B exist for HUAs 1, 5, 6, and 8 while 7 has only pose B
orientations. Neither 3 nor 4 have pose A or pose B due to the absence of -NHOH group.
Pose A orientations have the -NH2 of Asn148 as a hydrogen bond donor interacting
with the lone pair of the hydroxyl from the HUA. This hydroxyl group serves as the
hydrogen bond donor for the N of His75. The extensive hydrogen bond network
continues by the HN′ of the HUA hydrogen bonding with the oxoferryl group of CpdI
(Figure 3-5). Pose B orientations consist of a similar hydrogen bonding network with a
slight variation from pose A. In pose B, the hydrogen bond network is exclusively formed
by the -NHOH moiety (Figure 3-6). The HN is hydrogen bonded to the oxoferryl group
instead of the HN′ as in pose A. Both poses have the the -C=O moiety hydrogen bonded to
-NH2 of Gln168 of the HUA except for 1 in pose B. However, 1 in pose B still consists
of a hydrogen-bond with Gln168 formed by HN' atom. XP descriptors of the top scoring
poses in catalase CpdI were retained and analyzed (Table 3-1) along with the binding
orientations (Table 3-1A). The active site is stabilized by the extensive hydrogen bonding
network and a hydrophobic pocket created by Val73, Val74, Val116, Phe153,
Phe161,Pro162, Phe164, and Ile165. These stabilization interactions suggest that the
radical or anion intermediates of HUAs undergo transition state stabilization. Moreover,
significant movement of Phe161 and Ile165 is needed to accommodate bulky substituents
of HUAs ranging from ethyl to methoxyphenyl groups (Table 3-2) as observed by the
RMSD calculations undertaken using CHARMM program.
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Figure 3-5: Predicted pose A binding orientations of hydroxyurea analogs 1(5a) and
8(5b) in catalase CpdI. Carbons for CpdI, substrate and protein are colored in yellowgreen, yellow and cyan; oxygens, red; nitrogens, blue; hydrogens, light yellow; and iron,
magenta. Dotted red lines represent the hydrogen bonding interactions and the ribbons have
red for -helices and cyan for -sheets.

Figure 3-6: Predicted binding orientations of hydroxyurea analogs 1(6a), 7(6b) and 8(6c)
for pose B conformations in catalase CpdI. These analogs predominantly formed pose B
orientations than pose A like orientations. They all have same hydrogen bonding pattern
similar to hydrogen peroxide.
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Table 3-1. XP descriptor analysis showing the contribution of various GlideXP terms in kcal mol-1 for all pose A and pose B
conformations of HUA’s.
Title

GScore HBond

Phob

PhobEn Lipophilic RotPenal Penalties Electro Sitemap LowMW

EnHB

EvdW

1 - pose A

-5.16

-2.92

0.00

0.00

-0.53

0.00

0.05

-0.86

-0.40

-0.50

1 - pose B

-4.62

-2.55

0.00

0.00

-0.60

0.00

0.02

-0.58

-0.40

-0.50

3

-3.95

-1.89

0.00

0.00

-0.38

0.00

0.02

-0.80

-0.40

-0.50

4

-5.51

-2.93

0.00

0.00

-0.78

0.00

0.00

-0.90

-0.40

-0.50

5 - pose A

-8.41

-1.94

-1.39

-1.50

-3.04

0.55

0.28

-0.65

-0.22

-0.50

5 - pose B

-7.43

-2.77

0.00

-0.94

-2.89

0.55

0.13

-0.62

-0.40

-0.50

6 - pose A

-5.94

-2.55

0.00

-0.85

-2.22

1.37

0.14

-1.01

-0.31

-0.50

6 - pose B

-5.92

-2.78

0.00

-0.83

-2.16

1.37

0.10

-0.73

-0.40

-0.50

7 - pose B

-2.64

-2.13

0.00

0.00

-1.93

0.68

2.40

-0.83

-0.33

-0.50

8 - pose A

-7.39

-2.28

-1.50

0.00

-2.87

0.61

0.38

-0.83

-0.40

-0.50

8 - pose B

-5.84

-1.87

0.00

0.00

-3.26

0.61

0.02

-0.57

-0.28

-0.50
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Table 3-1A. Summary of IFD refinement binding orientaions (# corresponds to number)

1

NO
release
yes

yes

Top
pose
A

2

no

no

NA

NA

NA

NA

2

2

3

no

no

NA

83

NA

NA

2

2

4

no

no

NA

80

NA

NA

2

2

5

yes

yes

A

55

18

9

2

3

6

yes

yes

A

110

20

58

2

3

6a

NA

yes

B

32

2

18

2

2

6b

NA

yes

B

67

13

37

2

2

7

no

yes

B

22

0

16

2

2

8

NA

yes

A

60

17

25

3

3

HUA

NHOH

# binding poses
# Hydrogen bonds
Total poseA poseB acceptors donors
52
26
13
2
3

3. 4. 1 IFD results for all HUA's
N-hydroxyurea (1): Hydroxyurea, also known as hydroxycarbamide, is used as an
antisickling, antineoplastic agent.147,148 IFD produced an ensemble of 52 binding
orientations for 1. Clustering produced two dominant clusters with the following number
of poses in each cluster: Pose A (26) and pose B (13). Pose A (Figure 3-7a) had more
stabilization compared to pose B (Figure 3-7b) due to hydrogen bonding and electrostatics
confirmed by the XP descriptors (Table 3-1). After prime refinement, the residues that
experienced significant movement along with their respective side chain rmsd deviations
when compared to the apo structure of catalase CpdI for pose A were (Val116 - 1.36Å;
Ile165 - 1.04Å) whereas (Val116 - 1.35Å; Gln168 - 1.37Å) moved in pose B (Table 3-2).
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Table 3-2. Summary of flexible docking studies of HUA’s that caused the following
residues to undergo substantial conformational movements around 9 Å of oxoferryl
moiety in catalase CpdI in comparision to the starting structure (RMSDs in Å)

1
Residues

3

4

5

6

7

8

Val74

pose
A
0.20

pose
B
0.24

pose
A
0.09 0.07 0.28

pose
B
1.40

pose
A
0.32

pose
B
0.32 0.24

pose
A
0.60

pose
B
0.79

Val 116

1.36

1.35

0.21 1.36

0.12

1.35

0.10

0.42

0.05

0.09

0.13

Pro129

0.13

0.15

0.14 0.26

0.03

0.14

0.11

0.22

0.09

0.10

0.07

Gly131

0.02

0.03

0.04 0.04

0.04

0.04

0.04

0.04

0.04

0.04

0.04

Asn148

0.10

0.07

0.12 0.08

0.10

0.06

0.06

0.07

0.06

0.06

0.08

Phe153

0.08

0.06

0.65 0.11

0.09

0.09

0.05

2.24

0.08

0.09

0.08

Phe154

0.06

0.06

0.27 0.09

0.05

0.07

0.04

0.78

0.08

0.05

0.06

Phe161

0.20

0.08

0.07 0.05

2.73

2.79

2.94

1.37

2.91

3.18

3.17

Phe164

0.10

0.16

0.55 0.25

0.31

0.19

0.16

0.38

0.38

0.25

0.19

Ile165

1.04

0.06

0.11 0.12

0.70

0.21

0.93

0.17

0.96

1.16

1.23

Gln168

0.70

1.37

0.38 0.47

0.44

0.55

0.51

0.80

0.82

0.72

0.66

O-methyl N -hydroxyurea (3): This substrate commonly known as 1-methoxyurea
contains two donors and two acceptors available for hydrogen bonding. Experimental
results indicate that 3 failed to produce NO when interacting with Hb due to the absence
of the -NHOH group.88 IFD produced 83 orientations, but neither pose A or pose B can
produce C-nitroso formamide due to the lack of the -NHOH moiety. The major cluster
consisted of 27 docked conformations with the top scoring pose receiving energy
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stabilization from three hydrogen bonding interactions shown in appendix (Figure B-1a).
3 can form a diverse network of intermolecular hydrogen bonds (Figure 3-8a) in which
the Asn148 -NH2 group interacts with the -OCH3, while the N atom of His75 accepts two
hydrogen bonds from HN and HN′. Electrostatic interactions with His75, Asn148, Thr150,
and Gln168 also contribute to the stability of 3. IFD indicated that (Phe153 - 0.65; Å
Phe164 - 0.55 Å) experienced the most significant changes with the corresponding side
chain rmsd deviations compared to the apo structure (Table 3-2).
N -methyl N -hydroxyurea (4): Methyl hydroxyurea has two hydrogen bond donors and
two acceptors. 4 produced a nitroxide radical intermediate and had the highest rate constant
among the HUAs while interacting with Hb.88 However, it failed to form NO due to the
missing -NHOH group.146 Similar to 3, IFD resulted in 80 poses for 4 but did not produce
pose A or pose B and is not expected to interact with catalase CpdI to form C-ntroso
formamide. The major cluster retained 36 docked poses that closely resembled pose A
(Figure B-1b), but failed to hydrogen bond with the oxoferryl unit. In this cluster, a slightly
modified network of hydrogen bonds existed, in comparison to pose A; here, the interaction
of the oxoferryl oxygen with HN′ is replaced by HN′-

4 had a slightly larger Lipophilic

EvdW contribution than 1 due to the interaction between the methyl group present on the
NO with Pro129, Phe153, and Phe154. 4's electrostatic stabilization resulted from
interaction with Gln168, Asn148, and His75. Only (Val116 - 1.36Å) experienced
substantial structural changes in comparison to the apo structure (Table 3-2).
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Figure 3-7: 2D interaction energy diagram depicting the per residue interactions between
pose A and pose B conformations of hydroxyurea analogs 1, 5, 6 and 8 with catalase
CpdI active site residues. The legend representing the various symbols are presented in
Figure 8.
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Figure 3-8: 2D interaction diagram depicting the per residue interactions for hydroxyurea
analogs 3, 4 and 7 with catalase CpdI active site residues are shown in a, b and c. The
legend here represents the type of amino acid residues and the diferent interactions they
form.
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Figure 3-8B: Predicted binding orientations of HUAs 3, and 4 pose conformations in
catalase CpdI.
N' -phenyl N -hydroxyurea (5): HUA 5 (1-hydroxy-3-phenylurea) has three hydrogen
bond donors and two acceptors. It efciently released NO upon interacting with hemoglobin
and was found to have the second highest rate after 4.88 Subsequently, we attributed, this to
the transition state stabilization of the nitroxide radical caused by the HN' hydrogen bonding
to the Gly25 -C=O moiety along with strong hydrophobic interactions within hemoglobin's
hydrophobic cavity.146 IFD produced 55 orientations and after clustering, pose A was
dominant with 18 docked poses, while pose B had only 9 (Figure 3-9). Pose A had a better
binding affinity compared to pose B with respect to hydrogen bonding and the
LipophilicEvdW XP descriptors (Table 3-1). Furthermore, the phenyl group in 5 (pose A,
Figure 3-7c) possessed a

stacking interaction with Phe153. This contributed to the

large LipophilicEvdW score compared to pose B. Also, LipophilicEvdW interactions
between the phenyl group of 5 and Val74, Phe153, Phe161, Ile165, and Phe164 were
responsible for additional stabilization. IFD resulted in (Phe161 - 2.73Å and Ile165 - 0.70Å)
(Table 3-2) experiencing significant structural rearrangement compared to the apo form.
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Pose B (Figure 3-7d) was ranked third upon clustering, and had a significant
LipophilicEvdW contribution due to the phenyl moiety interacting with Val74, Phe153,
Ile155, Phe161, Ile165, and Phe164. The residues that underwent substantial changes in
pose B were Val74, Val116, Phe161, and Gln168. The side chain rmsd deviations were in
the range of (0.04 - 2.79Å) when compared to the apo structure of catalase CpdI (Table 32).

Figure 3-9: Predicted a)pose A and b)pose B binding orientations of 5 in catalase CpdI.
N' -n-butyl N -hydroxyurea (6): This derivative is commonly known as 1-butyl-3hydroxyurea with three sites for hydrogen bond donation and two acceptors. IFD produced
110 total poses. Clustering resulted in 20 pose A structures (Figure 3-7e) and 58 for pose B
(Figure 3-7f). Pose B was predicted to have slightly better binding affinity compared to pose
A. They had similar hydrogen bonding and LipophilicEvdW contributions as described by
the XP descriptors (Table 3-1). Furthermore, in the pose B orientation both HN and HN′ were
hydrogen bonded to the CpdI Fe=O moiety, whereas in pose A only the HN′ was hydrogen
bonded to Fe=O. Both orientations had an XP RotPenal of 1.37 kcal mol-1, which is a
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rotational penalty due to constricting the ﬂexible n-butyl chain of 6 in the hydrophobic
pocket. During IFD, the residues that experienced significant side chain movement for
poseA were (Phe161 - 2.94Å Ile165 - 0.93Å and Gln168 - 0.51Å) while (Phe153 - 2.24Å
Phe161 - 1.37Å and Gln168 - 0.80Å) moved most in pose B (Table 3-2).
N', N'-diethyl N-hydroxyurea (7): This analog is known as 1,1-diethyl 3-hydroxyurea and
consists of two donors and two acceptors for hydrogen bonding. 7 was the only HUA that
did not produce NO despite having an -NHOH group in Hb.88 Our previous ﬂexible docking
studies, determined that 7's inability to form NO was attributed to the absence of the HN′
atom.146 However, this analog may interact with catalase CpdI to produce NO as it contains
the essential -NHOH moiety required to form the C- nitroso formamide intermediate. IFD
resulted in 22 binding conformations, however, 7 did not form even a single pose A
confirmation. Clustering produced pose B (Figure 3-8c) as the preferred binding pose with
16 docked structures. Substrate 7 has a major XP penalty 2.4 kcal mol-1 coming from the
desolvation of the polar N' atom in a hydrophobic protein environment devoid of any
hydrogen bonding (Table 3-1). IFD results indicated that residues (Phe161 - 2.91Å Ile165 0.96Å and Gln168 - 0.82Å) experienced considerable side-chain movement (Table 3-2).
N' -4-methoxy phenyl N -hydroxyurea (8): HUA 8 (1-methoxy-3-phenylurea) contains
three hydrogen bond donors and three acceptors. Despite this substrate having the potential
to release NO while interacting with hemoglobin, experimental studies were not possible due
to solubility issues.88 8 has the potential to interact with catalase CpdI to produce NO due to
the presence of the -NHOH moiety. IFD yielded 60 poses as ranked by GlideXP scores.
Clustering produced 17 docked poses for pose A (Figure 3-7g) and 25 for pose B (Figure 37h). However, pose A had better predicted binding afnies in terms of hydrogen bonding by
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-1

E (Hbond + PhobEn Hb) = -1.91 kcal mol and LipophilicEvdW interactions (Table 3-1).
Both poses possessed a favorable LipophilicEvdW contribution due to the interaction of the
methoxyphenyl substituent with Val73, Val74, Phe153, Phe161, Phe164, and Ile165.
However, pose A had better predicted LipophilicEvdW due to additional interactions of the
methoxyphenyl group with Pro162. For both pose A and pose B, residues Phe153, Phe154,
Phe161, and Gln168 experienced considerable induced fit efects with side chain rmsds in
the range (0.04 - 3.18Å) compared to their apo structure (Table 3-2).
3.4.2

Proposed mechanism of action
The exact mechanism of the catalase catalyzed C-nitroso formamide formation from

HUA's remains unclear. IFD combined with available structural, biochemical, and
experimental studies revealed insight into the reaction mechanism.123,137,149,150 Upon careful
examination of docking orientations for pose A and pose B, it was observed that His75
could act as either an acid or base catalyst or provide stabilizing hydrogen bonds to the
HUA anion radicals produced during the course of the reaction. We propose four possible
reaction mechanisms for C-nitroso formamide generation (Figure 3-3) corresponding to
both pose A and B. We hypothesize that the hydroxyurea conversion occurs by the
reduction of catalase CpdI by either a His mediated or direct mechanism equivalent to
H2O2,137,151 as the -NHOH moiety of HUA represents an isostere of H2O2.
Pose A mechanism of actions
For pose A, the His mediated mechanism (Figure 3-10, top) involves interaction
of a HUA with catalase CpdI. This would quench the cation radical present on the
porphyrin ring by decomposing the double bond of oxoferryl to the hydroxyl-ferryl unit
(CpdII) via HN′ migration, forming a radical on N' (Figure 3-10, 2).
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Figure 3-10: Proposed reaction mechanism for HUA interaction with catalase CpdI for
pose A orientations. Reaction scheme involving His mediated mechanism of action and
reaction scheme describing direct mechanism of action.
This hydrogen migration from N' to the oxoferryl oxygen atom would be assisted
by the stabilizing interactions derived from the strong networked intermolecular
hydrogen bonds and hydrophobic pocket created by Val74, Val116, Pro129, Phe153,
Phe154, Phe161, Phe164, and Ile165. We hypothesize the radical would be localized on
the nitrogen rather than oxygen atom in HUAs during this process based on following.
Firstly, nitrogen radicals are commonly observed as they are more electron deficient than
carbon radicals. They also have similar stabilities to oxygen centered radicals due to
substituent effects.45 Further, gas phase DFT calculations on 2 by Vrcek et al.149 showed
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that N-centered radicals are frequently formed by hydrogen migrations. Calculated
mulliken spin densities showed that an unpaired electron on 2 would likely be located at
the O and NO atoms. It was previously shown using EPR, that O-centered radicals (2)
are the result of 1's interaction with human Hb.88 Nevertheless, these were not observed
in 1's interaction with catalase, illustrating the feasibility of other radical formations.123
From previous computational and experimental studies123,149,152 its reasonable to expect
competetion between the HN and HO for transfer to the N' radical. The transfer of the HN

 HN′ is corroborated by the resonance stabilization gained by NO radical, due to the
lone pair donation from the neighboring oxygen atom. In the subsequent step, the oxygen
atom would be deprotonated to generate an oxyanion. This is supported by Vrcek et al.149
who showed that 1 behaves as a hydroxamic acid with deprotonation occurring on the Ocenter to produce an oxyanion. Hence, it is hypothesized that the His75

plays a

catalytic role to abstract the HO to produce an oxyanion HUA radical moiety. Further,
reduction potential studies indicated that an electron from the oxyanion gets transfered to
metal ion oxidants.42 This observation indicates a negative charge on the oxygen moiety,
which switches to the N' radical and then transfers the radical to

to form reduced

. Finally, the oxygen of the hydroxyl-ferryl moiety would abstract the His75
proton yielding water, catalase (

), and C-nitroso formamide. In the case of the direct

mechanism (Figure 3-10), the initial step of the reaction is equivalent to its His mediated
counterpart. However, in the second step HO would get abstracted by the hydroxyl-ferryl
group instead of His75 to form an oxonium ion of CpdII (Figure 3-10). Later, similar to
pose A His mediated mechanism, the oxyanion charge would be transfered to reduce
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to

catalase, with the oxonium ion leaving the active site as water along with

C-nitroso formamide.
Pose B mechanism of actions

Figure 3-11: Proposed reaction mechanism for HUA interaction with catalase CpdI for
pose B orientations. Reaction scheme involving His mediated mechanism of action and
reaction scheme describing direct mechanism of action.
In the pose B mechanism (Figure 11), all analogs except 3 and 4 retained the
same array of intermolecular hydrogen bonds observed with the QM/MM optimized
H2O2-catalase CpdI complex.137 These networked intermolecular hydrogen bonds were
observed since the -NHOH moiety represents an isostere of H2O2. The pose B mechanisms
would differ from pose A with respect to hydrogen abstraction by the oxoferryl moiety.
Here, the oxoferryl would abstract the HN instead of HN′ to form CpdI and HU

radical

without the intermediacy of N' radical HU intermediate observed in pose A mechanism.
The His-mediated pose B mechanism is similar to pose A, except for the rearrangement of
HN atom to generate HU

radical. The remainder of the mechanism mimics that of pose
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A. Contrastingly, the pose B direct mechanism is significantly different. Following the
HN′ abstraction, the N-centered nitroxide radical would have to reorient itself by rotation
around the C-

bond to interact with hydroxy-ferryl moiety, leading to the formation of

C-nitroso formamide. Q-Chem 4.0144,145 was used to perform a torsional study of the Nhydroxyurea radical. The torsional optimization (O-

-C-N') was performed using

B3LYP/6-31G with a grid consisting of 75 radical shells and 302 angular points. The
torsion was constrained in 15° increments ranging from -180° to 180°. The torsional
profile rotating around the Cbarrier of 21.54 kcal

bond (Figure B-5) showed a large rotational energy

(Table 3-3). Due to this penalty, we conclude the pose B

direct mechanism would be unlikely to occur. However, if the reaction proceeds crossing
this high energy barrier, the reorientation will result in a sequence of

radical mediated

reactions. First breaking the hydroxyl group of HU into radicals leading to the formation
of C-nitroso formamide and

radical. Later the

radical induced another radical

formation by breaking hydroxy ferryl moiety to form water and catalase.
3.4.3 IFD dockings incorporating prime minimization
Based on the  -  angles of the amino acid backbone, the side-chain rotamer
library143 defines the most likely rotamer conformation based on its statistical occurrence
in the PDB. However, the correct states are less clear to the presence of water,
neighboring substrates, and co-factors. To account for the effect of co-factors like CpdI
and understand the effect of small molecules like 1 in the side chain movements, we have
also carried out IFD dockings using prime minimization.
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Table 3-3. B3LYP/6-31G
radical.

DFT study of the torsional potentials for N-hydroxyurea

HU
Radical
Torsion
-180

Energy
kcal mol-1

-165

0.88

-150

3.48

-135

7.37

-120

11.71

-105

15.46

-90

17.66

-75

17.79

-60

16.50

-45

14.86

-30

13.71

-15

13.61

0

14.92

15

17.73

30

21.54

45

14.86

60

16.50

75

17.79

90

17.66

105

15.46

120

11.71

135

7.37

150

3.48

165

0.88

180

0.00

0.00
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IFD prime minimization dockings produced only pose B orientations for 1, 5, 6, 7,
and 8. Only 5 produced the pose A orientation, however, pose B resulted in a lower
energy conformation. These results indicate that pose B is the most likely pose (Table 34).
Table 3-4. Summary of IFD prime minimization orientations (# corresponds to number
of)
HUA

Gscore

Top

# binding poses

kcal mol-1

pose

Total

1

-6.334

B

58

0

2

NA

NA

NA

3

-4.888

NA

4

-5.469

5

# Hydrogen bonds

pose A pose B

acceptors

donors

35

2

3

NA

NA

2

2

79

NA

NA

2

2

NA

62

NA

NA

2

2

-6.483

B

32

3

1

2

3

6

-5.872

B

66

0

30

2

3

7

-1.836

B

19

0

9

2

2

8

-6.889

B

30

0

6

3

3

3.4.4 Insights into the most likely mechanism of action.
IFD results have revealed four possible reaction mechanisms (Figure 10 and 11)
for HUAs; arising from pose A and pose B orientations. ProBiS,103-105 a web-based
binding site prediction and analysis tool (consisting of 31,198 non-redundant protein
structures) was used to scan existing heme-based enzymes. Results showed that the
catalase CpdI active site framework is unique. It failed to identify a single heme-based
protein with similar physiochemical properties to catalase CpdI, hence a singular
mechanism of action with HUAs is likely.
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During the examination of pose A and B for all HUAs, it was determined that 7
could form only the pose B orientation. This can be attributed to the absence of the HN′
atom. We were curious to the reason, that why 7 failed to generate even a single
confirmation looks like or close to pose A orientation even though HN′ hydrogen bonding
is missing. We started to analyze if the rationale was due to sterics or the lack of HN′ as 7
failed to form any orientation close to pose A. To identify the underlying cause, modified
analogs of 6 (Figure B-2) were generated, in which the HN′ was replaced with -CH3 (6a)
to create less sterically hindered structure. In the second analog we replaced the -NHN′
with a -CH2 group (6b) to study the importance of a polar HN′. IFD studies with 6a and
6b revealed that pose B is dominant. However, unlike 7 "Pose A like" confirmations
(Figure B-3), similar to pose A except for the HN′ hydrogen bonding interaction with the
oxoferryl moiety (Table 3-1A) were generated for 6a and 6b. Results from these analysis
clearly show that 7's inability to form pose A like confirmation is a consequence of
sterical clashes.
Moreover, results suggest that 6a, 6b, and 7 would interact with catalase CpdI to
produce NO as they contain the critical -NHOH group. This hypothesis is supported by
the interaction of hydroxylamine (NH2OH) with catalase CpdI to produce HNO.150
Considering that hydroxylamine produces HNO without an HN′ atom or amide functional
group, small molecules with an -NHOH moiety should be adequate to produce HNO. In
fact, hydroxylamine was shown to have a similar reaction profile to 1 when interacting
with catalase CpdI to produce HNO, as confirmed by EPR spectra.150 Later, the reductive
nitrosylation of ferric catalase by HNO produces the ferrous catalase-NO complex, an NO
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source (Figure B-4). To examine this in more detail we docked (with IFD)
hydroxylamine; this resulted only in pose B orientations.
Interestingly, the oxidation mechanisms of hydroxylamine150 and H2O2137 with
catalase should be very similar, again because they are isosteres. Overall, IFD results
conclude that, even though 6a and 6b produce pose A like confirmation, 6a, 6b and 7
cannot adopt the pose A mechanism of action (Figure 10) due to the absence of the N'
preventing them to form C-nitroso formamide. Previous spectroscopic and biochemical
studies along with current IFD results show that biosynthetic production of NO, from
possibly all HUAs, would occur predominantly via pose B orientations. Experimental
EPR and kinetics studies of these modified analogs with catalase would confirm proposed
reaction mechanisms (i.e. that pose B mechanism is dominant). Further, QM/MM studies
are underway to shed more light onto NO production via HUAs, interacting with hemebased enzymes.
3.5 Conclusions
The pharmacological efficacies of hydroxyurea therapy result from NO donation
causing the elevation of fetal Hb levels and vasodilation production preventing sickle cell
adhesion to endothelium cells. Catalase CpdI is an enzyme known to produce NO upon
interacting with HU; however, binding and mechanistic details remain unkown. Presently,
we examined nine hydroxyurea analogs (HUAs), including modified analogs complexed
with catalase CpdI using induced fit docking (IFD) coupled with scoring function
decomposition. Our work revealed an important network of intermolecular hydrogen
bonds created by distal residues His75, Asn148, Gln168, and oxoferryl-heme to HUAs.
Also, strong hydrophobic interactions were conferred to substrates by the active site
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residues Val73, Val74, Val116, Phe153, Phe161,Pro162, Phe164, and Ile165. Further,
Phe161 was identified to undergoes significant induced fit effects to accommodate
aromatic substrates like 5 and 8. We proposed reaction mechanisms using information
obtained from predicted binding modes coupled with available biochemical data.
Bioinfromatics results, obtained via binding site analysis (i.e ProBiS) indicated
that catalase CpdI could have a unique mechanism of action compared to nearly all hemebased enzymes. Moreover, the similarities in structural, physiochemical, and biological
action between hydroxyurea, hydroxylamine, and hydrogen peroxide confirms the
likelihood of the pose B His-mediated pathway due to a high rotational energy barrier that
is required in the direct mechanism. Further analysis of the 6a, 6b, and 7 docking poses
suggested that pose B is favored due to accommodation of bulky substituents and
avoidance of sterical clashes. These dockings along with the hydroxylamine biochemical
data show that a -NHOH moiety, an isostere to H2O2, is necessary to produce NO and will
most likely occur via the pose B His-mediated mechanism. Structural and mechanistic
details of HUAs and catalase CpdI should serve as a model for continued structure based
drug design, specifically targeting new scaffolds with -NHOH as the pose pharmacaphore.
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Chapter 4: Computational correlation studies towards inactivation
of O6- alkylguanine-DNA alkyltransferase by O6-benzylguanine
analogs
Note to the Reader
Portions of this chapter comprising my computational work has been previously
published as Pauly, G.T.; Loktionova, N. A.; Fang, Q.; Vankayala, S. L.; Guida, W. C.;
Pegg, A. E.
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4.1 Abstract
The main forms of cancer treatment are Chemotherapy and Radiation therapy. As
part of chemotherapy, various alkylating agents are used to induce DNA damage. Most of
these alkyl lesions are mutagenic and can be highly cytotoxic as secondary effects.
Eventually cells have evolved with various mechanisms to detect and repair DNA

75

damage, resulting in therapeutic resistance.

O6-alkylguanine-DNA alkyltransferase

(AGT) is a DNA repair protein that acts in a single step to restore DNA with O6Alkylguanine lesions, and thus prevents mutations and apoptosis arising from alkylated
guanines. A novel strategy has been explored to reverse this drug resistance by inhibiting
the DNA repair pathways to enhance chemo and radio sensitivity. So various analogs of
benzyl guanine were synthesized and tested for activity as potential inhibitors of AGT.
The nature and position of the substitutions involving methyl and aminomethyl groups
profoundly affected their activity. Molecular modeling studies of their interactions with
alkyltransferase provided a molecular explanation for these results. The square of the
correlation coefficient (R2) obtained between E-model scores (obtained from GLIDE
XP/QPLD docking calculations) vs. log(IC50) values via a linear regression analysis was
0.95. The models indicate that the ortho- substitution causes a steric clash interfering
with binding whereas the meta- aminomethyl substitution allows an interaction of the
amino group to generate an additional hydrogen bond with the protein for its enhanced
activity. Virtual screening using NCI diversity set 2 against this AGT protein model lead
to the discovery 7 novel lead molecules.
4.2 Introduction
O6-Alkylguanine-DNA alkyltransferase is a unique DNA repair protein that acts
in a single step to restore DNA with O6-alkylguanine adducts by transferring the alkyl
group to an acceptor site, which in human alkyltransferase is located at Cys145.153-155
Alkyltransferase activity in tumors is an important source of resistance to therapeutic
alkylating agents such as dacarbazine, temozolomide, 1,3-bis(2-chloroethyl)-1nitrosourea

(BCNU)

or

1-(2-chloroethyl)-3-(trans-476

methylcyclohexyl)-1-

nitrosourea.153,154,156-160 O6-Benzylguanine has been shown to be a potent inhibitor of
human alkyltransferase. O6-Benzylguanine acts as a pseudosubstrate. After binding in the
active site, it leads to the formation of S-benzylcysteine at the Cys145 acceptor site
irreversibly

inactivating

the

protein.161-163

A

related

compound

O6-(4-

bromothenyl)guanine was found to be a slightly more potent inactivator of
alkyltransferase164 and is thought to act in the same way. Both compounds are undergoing
clinical trials.156,159,160,165-170 Although there have been some responses in these trials
providing proof of concept for the target, it is clear that improved inhibitors will be
needed.

Figure 4-1: Direct reversal pathway repairing DNA damage by reversing the alkylation
on O6-guanine.
Since the original development of O6-benzylguanine, structural and biochemical
studies have provided a much greater understanding of the repair reaction catalyzed by
alkyltransferase and the binding and reaction of this inhibitor. After binding the substrate
DNA via the minor groove using a helix-turn-helix motif, the alkyltransferase protein
brings about a change in the DNA structure which rotates the alkylated guanine
deoxynucleoside from the base stack into an active site pocket which contains the Cys145
acceptor residue.155,171 This places the O6-alkylguanine in the correct position for repair
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in a hydrophobic cleft where the Cys145 and Val148 carbonyls accept hydrogen bonds
from the exocyclic amine of the guanine, the N of Ser159 donates a hydrogen bond to the
substrate guanine-O6, and the hydroxyl of Tyr114 donates hydrogen bonds to guanine-N3
(Figure 4-1). These interactions exactly position the alkyl group for attack by Cys145.
This residue is highly reactive by virtue of its activation to a thiolate anion by a
Glu172:His146:water:Cys145 hydrogen bond network.155,163,172 O6-Benzylguanine binds
much more weakly at the active site pocket since all of the interactions with the
alkyltransferase-DNA binding domain are lost but it is held in a position that allows
attack by Cys145 via the interactions with the guanine moiety described above and the
interaction of the benzyl group with the side-chain of Pro140.155,163 Mutation of this Pro
residue profoundly reduces the ability of O6-benzylguanine to inactivate human
alkyltransferase.173,174 Despite the weak binding, the reactivity of benzyl in bimolecular
displacement reactions such as that occurring in the alkyltransferase active site facilitates
the inactivating reaction. However, the rate constant for the reaction with O6benzylguanine free base is only c. 600 M-1. sec-1,162 which is >10,000 times less than that
for the repair of O6-methylguanine in DNA and or of oligodeoxyribonucleotides
containing O6-benzylguanine, which are much more potent inactivators.175,176 Such
oligodeoxyribonucleotides are not ideal for clinical use and other attempts to improve the
binding of low M.W. pseudosubstrates are needed.
We

have

now

undertaken

in

silico

screening

of

three

O6-

[(aminomethyl)benzyl]guanines (compounds 1- 3) and three O6-(methylbenzyl)guanines
(compounds 5-7) shown in Figure 4-2. It was found that the nature and position of the
substitution profoundly affected the ability to inactivate human alkyltransferase.
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Molecular modelling studies using one of the crystal structures available for the protein
and its interaction with compounds 1-3, 5-7 and O6-benzylguanine were carried out and
provide a plausible explanation for these results and show that the meta-substituent on
O6-[3-(aminomethyl)benzyl]guanine (2) provides additional interactions with the active
site pocket that increase the affinity for O6-benzylguanine derivatives and generates a
more potent and soluble alkyltransferase inhibitor. Later, with the successful prediction
of relative binding affinities, we further used the model to unveil novel lead molecule by
virtual screening studies using NCI diversity set2 followed by biological testing.
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Figure 4-2: Substituted O6-benzylguanines and an N6-[(hydroxymethyl)benzyl]-2aminoadenine resulting from a rearrangement of 3.
4.3 Methods
The computational modeling studies relied upon the GLIDE (Grid-based Ligand
Docking from Energetics) program (Glide, version 4.5, Schrödinger, LLC New York, NY
2007)177-179 for the docking simulations. These simulations were performed using the Xray crystal structure of the human alkyltransferase bound to a DNA oligonucleotide and
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containing O6-methylguanine determined at 3.2 Å resolution (PDB ID:1T38).171,180 For
our studies, DNA was removed except for O6-methylguanine, see Figure 4-3. Solvent
molecules in the protein crystal structure were deleted, except for a water molecule in the
active site (WAT 1), and the protein was then prepared for the docking studies by
processing it using Schrödinger’s protein preparation facility. This procedure minimizes
the protein to 0.30 Å RMSD using the OPLS-2001 force field. Later the protein/ligand
complex was taken and pursued Macromodel Mixed torsional /Low-mode sampling
conformational search (MacroModel, version 9.5, Schrödinger, LLC, New York, NY,
2007). This procedure employed OPLS 2001 force field, with a distance-dependent
electrostatic treatment with 2.0 units of dilectric constant.

Figure 4-3: Prepared protein of the human alkyltransferase without DNA.
methylguanine and WAT1 also shown.
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O6-

A 5Å shell of residues around the native ligand and water molecule were allowed
to undergo energy minimization. Later ASN 157 and ARG 135 residues along with the
rest of the protein residues were frozen for the conformational search. The ligand was
allowed to translate and rotate in the active site and generated 892 conformers.
The lowest energy conformer that retained the native ligand pose in the X-ray
crystal structure of PDB 1T38 was carried for further studies. O6-Methylguanine, O6benzylguanine and the O6-benzylguanine derivatives were prepared using Schrodinger’s
LigPrep facility. The initial docking studies were done with GLIDE (version 4.5,
Schrödinger, LLC, New York, NY, 2007) operating in either SP or XP mode.177-179
Maestro, version 8.0, Schrödinger Suite 2007, LLC New York, NY 2007) was employed
as the graphical user interface and for generation of the graphics used in the figures. The
best docked structure were chosen using the Glide_gscore function (Glide Score). For
enhanced docking accuracy the best docked structures from XP were used to calculate the
ligand partial charges and then redocked using Schrödinger’s QPLD (Quantum Polarized
Ligand Docking) method. In order to validate the docking approach, self docking was
performed using the partial native ligand O6-methylguanine using XP/QPLD. The RMS
of the docked pose when compared to the crystallographically observed position was 0.14
Å, and thus GLIDE produced a docking mode that closely resembled the X-ray crystal
structure.
4.4 Results and Discussion
Computational docking studies were performed using the GLIDE program
(version 4.5, Schrödinger, LLC, New York, NY, 2007). The docked structures were
chosen for comparison with experimentally determined EC50 values using either the
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Glide Score or Emodel scoring function. For enhanced docking accuracy the best docked
structures using GLIDE extra precision (XP) mode were used to calculate ligand partial
charges in the protein environment and then redocked with XP using Schrödinger’s
QPLD (Quantum Polarized Ligand Docking) method.181 The Maestro user interface,
(version 8.0, Schrödinger, LLC, New York, NY, 2007) was employed to set up the
GLIDE docking studies and for visualization of the results. The AGT X-ray crystal
structure chosen for our modeling studies was human alkyltransferase bound to DNA
containing O6-methylguanine and Cys145 mutated to serine to prevent the alkylation
reaction from taking place.171 In our modeling studies, Ser145 was mutated back to
cysteine. To validate the docking approach, self-docking was performed with XP/QPLD
using the partial native ligand: O6-methylguanine. The RMS of the docked pose when
compared to the crystallographically observed position of the O6-methylguanine moiety
was 0.14 Å, and thus GLIDE produced a docking mode that closely resembled the X-ray
crystal structure. Thus, our hypothesis was that GLIDE would be capable of producing
docking poses for the compounds studied that are similar to the position, orientation and
conformation adopted by the ligands prior to nucleophilic attack by Cys145 and that the
docking scores obtained would correlate well with the experimentally observed ED50
values for enzyme inactivation. Although there is a crystal structure available for human
alkyltransferase benzylated at Cys145.163 this structure was not employed to model the
O6-benzylguanine analogs described in this study since the GLIDE program is unsuitable
for modeling covalent bonds formed between the ligand and protein.
In addition to O6-methylguanine, compounds 1-3, 5-7 and O6-benzylguanine were
docked to human alkyltransferase using the GLIDE XP. Each pose of these compounds
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was redocked with XP using the QPLD method. The coefficient of determination (i.e.,
the square of the correlation coefficient, R2) was calculated between QPLD Glide Scores
vs. log(ED50) values, determined in the presence of DNA, as part of a linear regression
analysis. An acceptable R2 value of 0.86 between log(ED50) values and XP/QPLD Glide
Scores was obtained (Figure 4-4).
Emodel scores were also used for correlation studies. It had been previously
observed by Bytheway and Cohran182 that Emodel scores correlated better with log(ED50)
values than Glide Scores in their particular study. In our study, the coefficient of
determination obtained between E-Model scores (obtained from XP/QPLD calculations)
vs. log(ED50) values via a linear regression analysis gave an exceptional R2 of 0.96,
shown in Figure 4-5. It is noteworthy that Emodel is a composite scoring function,
derived from a combination of the Glide Score itself coupled with Coulombic energy, van
der Waals energy, and ligand strain energy terms, and is used by GLIDE to select the best
docking pose for each individual inhibitor regardless of the scoring function subsequently
used and to rank order the inhibitors. Emodel scores were also used for correlation
studies. It had been previously observed by Bytheway and Cohran182 that Emodel scores
correlated better with Log(ED50) values than Glide Scores in their particular study. In our
study, the correlation coefficient obtained between Emodel (obtained from XP/QPLD
calculations) vs. Log(ED50) via a linear regression analysis gave an exceptional
correlation coefficient of 0.99, shown in Figure 4-5. It is noteworthy that Emodel is a
composite scoring function, derived from a combination of the Glide Score itself coupled
with Coulombic energy, van der Waals energy, and ligand strain energy terms, and is
used to both select the best docking pose for each inhibitor and rank order the inhibitors.
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QPLD_Glide_scores Vs log(ED50)

R² = 0.8638
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Figure 4-4:
Plot of log(ED50) values versus QPLD_Glide_scores. Numbering
corresponds to compounds listed in Table 3. The ED50 values determined in the presence
of DNA from Table 2 were used.
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compounds listed in Table3. The ED50 values determined in the presence of DNA from
Table 2 were used.
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From examination of the QPLD based docking modes, one can conclude that the
binding affinities correlate quite well with the number of hydrogen bonds and good van
der Waals contacts formed between the inhibitor and the alkyltransferase binding site.
There is insufficient space to adequately accommodate the ortho substituted
benzylguanines. Thus, due to fewer favorable van der Waals contacts and due to their
fewer hydrogen bonds, compounds 3 and 7 are the least potent of the inhibitors we tested
in the present study. On the other hand, compounds 1 and 2 exhibit four and three
hydrogen bonds respectively and both form good van der Waals contacts with the
receptor. The main reasons for enhanced effectiveness compared to other analogs.
Further, the ortho analogs have the lowest hydrogen bonds. All the values of these
parameters are summarized in Table 2.
Table 4-2. Docking parameters derived from docking compounds 1-3, 5-7, O6benzylguanine and O6-methylguanine to human alkyltransferase.
Compound
Number

Inhibitor

E-model
Score

Glide H-bonds
Score

Good
vdw
Contacts
297

2

O6-[3-(aminomethyl)benzyl]guanine

-88.1

-9.42

4

1

O6-[4-(aminomethyl)benzyl]guanine

-82.0

-9.46

3

312

5

O6-[4-(methyl)benzyl]guanine

-81.5

-9.54

3

306

O6-benzylguanine

-78.2

-8.79

3

287

O -[3-(methyl)benzyl]guanine

-77.5

-9.30

3

289

O6-methylguanine

-56.6

-7.16

4

177

3

O6-[2-(aminomethyl)benzyl]guanine

-52.2

-6.75

2

260

7

O6-[2-(methyl)benzyl]guanine

-52.0

-6.12

1

180

6

6
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Figure 4-6 shows the key hydrogen bonding interactions of compound 2 with
human alkyltransferase. Interactions with residues Tyr114, Cys145, Ser159 and Asn137
are seen. (All except for the interaction with Tyr114 involve interaction with protein
backbone rather than the amino acid side chains.)

Figure 4-6: The key hydrogen bonding interactions of compound 2 (O6-[3(aminomethyl)benzyl]guanine) with the protein residues represented in stick model. The
inhibitor is represented in green for carbon, blue for nitrogen and red for oxygen. The rest
of the protein as pale green ribbon cartoon.

Figure 4-7 shows an overlay of all of the inhibitor poses in the active site with O6methylguanine. It is clearly apparent that compounds 3 and 7 are not oriented in the
catalytic site of human alkyltransferase in same way as the other inhibitors. Having
obtained a co-efficient of determination close to 0.96 and visual inspection of all the
analogs clearly validated our model by accurately predicting weak inhibitor capabilities
of ortho substituents. Further, we used this AGT model to virtually screen the NCI
Diversity Set 2 consisting of 1880 small molecules. After the virtual screening using the
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GlideXP scoring function we retained the top 50 molecules and they were tested for
biological activity by Dr. Natalia A Loktionova, and Dr. Sreenivas. We found 7 novel
lead compounds that caused the following % of AGT activity to remain at 200 μM of
these small molecule concentrations (Figure 4-8).

Figure 4-7: Overlay of the position of all of the docked compounds in the human
alkyltransferase active site with the native ligand O6-methylguanine and parent inhibitor
O6-benzylguanine. All of the potent inhibitor poses (compounds 1, 2, 5, 6 and O6benzylguanine) in green are oriented in the same way as the native ligand O6methylguanine. The ineffective inhibitors O6-[2-(aminomethyl)benzyl]guanine (3) in red
and O6-[2-(methyl)benzyl]guanine (7) in yellow are not oriented in the same way as O6methylguanine. The rest of the color code is the same as Fig 4.
We found an interesting observation that our virtual screening studies identified
NSC 45383 to be streptonigrin, an aminoquinone known to have antitumour and
antibacterial properties. Moreover, this compound functions through DNA inhibition, and
induces DNA strand breaks, however, the target enzyme is not known till date. Hence our
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model helped identify an already existing inhibitor and identified AGT as its target
(Figure 4-9).

Figure 4-8: AGT activity remaining (%) at 200 uM of the following NSC drugs
4.5 Conclusion
The addition of a meta aminomethyl group to O6-benzylguanine forming compound 2
results in an approximately 20-fold improvement in the ability to inactivate purified
human alkyltransferase. This improvement is seen in assays conducted with or without
added DNA. It is noteworthy that the molecular modeling studies showed a similar trend
and an R2 of 0.90 (data not shown) for a linear regression analysis of log(ED50),
determined in the absence of DNA, vs. XP/QPLD Glide Scores and an R 2 of 0.98 (data
not shown) for log(ED50), determined in the absence of DNA, vs. Emodel scores were
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obtained. As previously noted, inactivation of alkyltransferase by O6-benzylguanine183 is
enhanced 3-4 –fold by the presence of DNA, which stimulates the rate of alkyl
transfer.184
In contrast, some O6-benzylguanine derivatives with bulky substituents are much
less potent inhibitors in the presence of DNA since they cannot be accommodated in the
active site when DNA is bound there

184,185

. The inactivation of alkyltransferase by

compounds 1 and 2 was increased by the presence of DNA indicating that these
compounds, like O6-benzylguanine, do not compete with DNA for access to the active
site. However compound 1, the para aminomethyl- derivative did not show any
improvement in inhibitory potency over O6-benzylguanine itself. These results are very
well explained by the molecular modelling studies, which indicate the formation of an
additional hydrogen bond when compound 2 is bound in the active site. The aminomethyl
group from 2 but not 1 is able to interact with Asn137. This also explains why a simple
methyl substitution (compound 6) was ineffective since it cannot form this bond. The
modelling studies also show clearly why the ortho- substituted O6-benzylguanine
derivatives (3 and 7) are much less effective (> 200-fold) than O6-benzylguanine since,
due to steric clashes, they cannot be positioned in the same way as the parent compound.
Our results not only demonstrate that 2 may be a valuable alkyltransferase
inhibitor but they also show clearly the value of molecular modelling for the design of
improved alkyltransferase inhibitors. The remarkable correlation coefficient obtained
using XP/QPLD via E-Model and the compounds tested here shows that the available
structures of human alkyltransferase can clearly be used for this process. The remarkable
R2 values obtained using XP/QPLD with E-Model scoring for ranking the compounds
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tested here shows that the structure of human alkyltransferase bound to DNA containing
O6-methylguanine and Cys145 mutated to serine can clearly be used as a starting
structure for this process. The mutation of Ser145 back to Cys, as is appropriate for the
wild type enzyme, and refinement of the structure obtained with MacroModel was
essential in order to obtain the R2 values we report.

Figure 4-9: The key hydrogen bonding interactions of streptonigrin (NSC 45383) with the
protein residues represented in stick model. The inhibitor is represented in brown for
carbon, blue for nitrogen and red for oxygen. The rest of the protein as magneta ribbon
cartoon.
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The model we have generated should be highly useful in the design of more potent
inhibitors by performing additional modeling studies on O6-benzylguanine analogs and
by virtually screening databases of commercially available compounds to identify
potential new lead compounds for further elaboration. And we started with the GlideXP
virtual screening studies of NCI Diversity set2 (NCId2) obtained from NIH to our AGT
model produced more than 100 lead hits that can inhibit AGT. When our collaborators
tested for their % of AGT biological activity remaining at 200 μM for all these 50 top
scoring compounds, we identified 7 novel lead compounds.
Interestingly, we observed that our studies discovered the NSC 45383 to be
streptonigrin, an aminoquinone known to have antitumour and antibacterial properties
(Figure 4-9). Until now the exact target is unknown, but our studies clearly showed that
AGT remains as its prime target to inhibit DNA synthesis. As part of my future research,
studies involves finding Lead molecules to inhibit AGT protien. So presently pursuing
virtual screening docking studies by docking large libraries of Zinc Leadlike compounds
( around 1.8 million compounds) in the Global energy conformer of AGT 1T38 obtained
through GlideXP virtual screening studies.

4.6 Acknowledgments:
I would like to thank my collaborators for their biological studies supporting this
work, Dr. Natalia A Loktionova, Dr. Sreenivas and Dr. Anthony Pegg from The
Pennsylvania State University College of Medicine, P.O. Box 850, Hershey,
Pennsylvania 17033.

91

Bibliography
1.
Cheng, T.; Li, Q.; Zhou, Z.; Wang, Y.; Bryant, S. H., Structure-based virtual
screening for drug discovery: a problem-centric review. AAPS J 2012, 14, 133-141.
2.
Leeson, P., DRUG DISCOVERY Chemical beauty contest. Nature 2012, 481,
455-456.
3.
C, B. R.; Subramanian, J.; Sharma, S. D., Managing protein flexibility in docking
and its applications. Drug Discov Today 2009, 14, 394-400.
4.
Boehr, D. D.; Nussinov, R.; Wright, P. E., The role of dynamic conformational
ensembles in biomolecular recognition. Nat Chem Biol 2009, 5, 789-796.
5.
Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.;
Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T., Extra Precision Glide: Docking and
Scoring Incorporating a Model of Hydrophobic Enclosure for Protein-Ligand Complexes.
J. Med. Chem. 2006, 49, 6177-6196.
6.
Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D.,
Improved protein-ligand docking using GOLD. Proteins-Structure Function and
Genetics 2003, 52, 609-623.
7.
Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R.
K.; Olson, A. J., Automated docking using a Lamarckian genetic algorithm and an
empirical binding free energy function. Journal of Computational Chemistry 1998, 19,
1639-1662.
8.
Kramer, B.; Rarey, M.; Lengauer, T., Evaluation of the FLEXX incremental
construction algorithm for protein-ligand docking. Proteins 1999, 37, 228-241.
9.
Moitessier, N.; Englebienne, P.; Lee, D.; Lawandi, J.; Corbeil, C. R., Towards the
development of universal, fast and highly accurate docking/scoring methods: a long way
to go. British Journal of Pharmacology 2008, 153, S7-S26.
10.
Huang, S.-Y.; Grinter, S. Z.; Zou, X., Scoring functions and their evaluation
methods for protein-ligand docking: recent advances and future directions. Phys. Chem.
Chem. Phys. 2010, 12, 12899-12908.
11.
Meng, X. Y.; Zhang, H. X.; Mezei, M.; Cui, M., Molecular docking: a powerful
approach for structure-based drug discovery. Curr Comput Aided Drug Des 2011, 7, 146157.
92

12.
Moustakas, D. T.; Lang, P. T.; Pegg, S.; Pettersen, E.; Kuntz, I. D.; Brooijmans,
N.; Rizzo, R. C., Development and validation of a modular, extensible docking program:
DOCK 5. J Comput Aided Mol Des 2006, 20, 601-619.
13.
Raub, S.; Steffen, A.; Kamper, A.; Marian, C. M., AIScore chemically diverse
empirical scoring function employing quantum chemical binding energies of hydrogenbonded complexes. J Chem Inf Model 2008, 48, 1492-1510.
14.
Sotriffer, C. A.; Sanschagrin, P.; Matter, H.; Klebe, G., SFCscore: scoring
functions for affinity prediction of protein-ligand complexes. Proteins 2008, 73, 395-419.
15.
Bohm, H. J., LUDI: rule-based automatic design of new substituents for enzyme
inhibitor leads. J Comput Aided Mol Des 1992, 6, 593-606.
16.
Eldridge, M. D.; Murray, C. W.; Auton, T. R.; Paolini, G. V.; Mee, R. P.,
Empirical scoring functions: I. The development of a fast empirical scoring function to
estimate the binding affinity of ligands in receptor complexes. J Comput Aided Mol Des
1997, 11, 425-445.
17.
Xue, M.; Zheng, M.; Xiong, B.; Li, Y.; Jiang, H.; Shen, J., Knowledge-based
scoring functions in drug design. 1. Developing a target-specific method for kinaseligand interactions. J Chem Inf Model 2010, 50, 1378-1386.
18.
Ishchenko, A. V.; Shakhnovich, E. I., SMall Molecule Growth 2001
(SMoG2001): an improved knowledge-based scoring function for protein-ligand
interactions. J Med Chem 2002, 45, 2770-2780.
19.

Muegge, I., PMF scoring revisited. J Med Chem 2006, 49, 5895-5902.

20.
Mooij, W. T.; Verdonk, M. L., General and targeted statistical potentials for
protein-ligand interactions. Proteins 2005, 61, 272-287.
21.
Zhao, X.; Liu, X.; Wang, Y.; Chen, Z.; Kang, L.; Zhang, H.; Luo, X.; Zhu, W.;
Chen, K.; Li, H.; Wang, X.; Jiang, H., An improved PMF scoring function for universally
predicting the interactions of a ligand with protein, DNA, and RNA. J Chem Inf Model
2008, 48, 1438-1447.
22.
Terp, G. E.; Johansen, B. N.; Christensen, I. T.; Jorgensen, F. S., A new concept
for multidimensional selection of ligand conformations (MultiSelect) and
multidimensional scoring (MultiScore) of protein-ligand binding affinities. J Med Chem
2001, 44, 2333-2343.
23.
Wang, R. X.; Lai, L. H.; Wang, S. M., Further development and validation of
empirical scoring functions for structure-based binding affinity prediction. Journal of
Computer-Aided Molecular Design 2002, 16, 11-26.

93

24.
Clark, R. D.; Strizhev, A.; Leonard, J. M.; Blake, J. F.; Matthew, J. B., Consensus
scoring for ligand/protein interactions. J Mol Graph Model 2002, 20, 281-295.
25.
Kitchen, D. B.; Decornez, H.; Furr, J. R.; Bajorath, J., Docking and scoring in
virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov
2004, 3, 935-949.
26.
Meiler, J.; Baker, D., ROSETTALIGAND: Protein-small molecule docking with
full side-chain flexibility. Proteins-Structure Function and Bioinformatics 2006, 65, 538548.
27.
Abagyan, R.; Totrov, M.; Kuznetsov, D., Icm - a New Method for Protein
Modeling and Design - Applications to Docking and Structure Prediction from the
Distorted Native Conformation. Journal of Computational Chemistry 1994, 15, 488-506.
28.
Clark, K. P.; Ajay, Flexible Ligand Docking without Parameter Adjustment
across 4 Ligand-Receptor Complexes. Journal of Computational Chemistry 1995, 16,
1210-1226.
29.
Morris, G. M.; Goodsell, D. S.; Huey, R.; Olson, A. J., Distributed automated
docking of flexible ligands to proteins: Parallel applications of AutoDock 2.4. Journal of
Computer-Aided Molecular Design 1996, 10, 293-304.
30.
Welch, W.; Ruppert, J.; Jain, A. N., Hammerhead: fast, fully automated docking
of flexible ligands to protein binding sites. Chem Biol 1996, 3, 449-462.
31.
Totrov, M.; Abagyan, R., Flexible ligand docking to multiple receptor
conformations: a practical alternative. Curr Opin Struct Biol 2008, 18, 178-184.
32.
Cavasotto, C. N.; Abagyan, R. A., Protein flexibility in ligand docking and virtual
screening to protein kinases. J Mol Biol 2004, 337, 209-225.
33.
Jiang, F.; Kim, S. H., Soft Docking - Matching of Molecular-Surface Cubes.
Journal of Molecular Biology 1991, 219, 79-102.
34.
Ferrari, A. M.; Wei, B. Q.; Costantino, L.; Shoichet, B. K., Soft docking and
multiple receptor conformations in virtual screening. J Med Chem 2004, 47, 5076-5084.
35.
Leach, A. R., Ligand docking to proteins with discrete side-chain flexibility.
Journal of Molecular Biology 1994, 235, 345-356.
36.
Kolossvary, I.; Guida, W. C., Low-mode conformational search elucidated:
application to C39H80 and flexible docking of 9-deazaguanine inhibitors into PNP. J.
Comput. Chem. 1999, 20, 1671-1684.

94

37.
Alberts, I. L.; Todorov, N. P.; Dean, P. M., Receptor flexibility in de novo ligand
design and docking. J Med Chem 2005, 48, 6585-6596.
38.
Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell,
D. S.; Olson, A. J., AutoDock4 and AutoDockTools4: Automated docking with selective
receptor flexibility. Journal of Computational Chemistry 2009, 30, 2785-2791.
39.
Taylor, R. D.; Jewsbury, P. J.; Essex, J. W., FDS: flexible ligand and receptor
docking with a continuum solvent model and soft-core energy function. Journal of
Computational Chemistry 2003, 24, 1637-1656.
40.
Carlson, H. A., Protein flexibility and drug design: how to hit a moving target.
Curr Opin Chem Biol 2002, 6, 447-452.
41.
Bottegoni, G.; Kufareva, I.; Totrov, M.; Abagyan, R., Four-dimensional docking:
a fast and accurate account of discrete receptor flexibility in ligand docking. J Med Chem
2009, 52, 397-406.
42.
Claussen, H.; Buning, C.; Rarey, M.; Lengauer, T., FlexE: efficient molecular
docking considering protein structure variations. Journal of Molecular Biology 2001,
308, 377-395.
43.
Knegtel, R. M.; Wagener, M., Efficacy and selectivity in flexible database
docking. Proteins 1999, 37, 334-345.
44.
Najmanovich, R.; Kuttner, J.; Sobolev, V.; Edelman, M., Side-chain flexibility in
proteins upon ligand binding. Proteins-Structure Function and Genetics 2000, 39, 261268.
45.
Sherman, W.; Beard, H. S.; Farid, R., Use of an induced fit receptor structure in
virtual screening. Chem. Biol. Drug Des. 2006, 67, 83-84.
46.
Sherman, W.; Day, T.; Jacobson, M. P.; Friesner, R. A.; Farid, R., Novel
Procedure for Modeling Ligand/Receptor Induced Fit Effects. J. Med. Chem. 2006, 49,
534-553.
47.
Wagener, M.; Vlieg, J. D.; Nabuurs, S. B., Flexible protein-ligand docking using
the Fleksy protocol. J Comput Chem 2012.
48.
Jacobson, M. P.; Friesner, R. A.; Xiang, Z.; Honig, B., On the Role of the Crystal
Environment in Determining Protein Side-chain Conformations. J. Mol. Biol. 2002, 320,
597-608.
49.
Jacobson, M. P.; Kaminski, G. A.; Friesner, R. A.; Rapp, C. S., Force Field
Validation Using Protein Side Chain Prediction. J. Phys. Chem. B 2002, 106, 1167311680.
95

50.
Bottegoni, G.; Kufareva, I.; Totrov, M.; Abagyan, R., A new method for ligand
docking to flexible receptors by dual alanine scanning and refinement (SCARE). J
Comput Aided Mol Des 2008, 22, 311-325.
51.
Koska, J.; Spassov, V. Z.; Maynard, A. J.; Yan, L.; Austin, N.; Flook, P. K.;
Venkatachalam, C. M., Fully Automated Molecular Mechanics Based Induced Fit
Protein-Ligand Docking Method. Journal of Chemical Information and Modeling 2008,
48, 1965-1973.
52.
Spassov, V. Z.; Yan, L.; Flook, P. K., The dominant role of side-chain backbone
interactions in structural realization of amino acid code. ChiRotor: a side-chain prediction
algorithm based on side-chain backbone interactions. Protein Sci 2007, 16, 494-506.
53.
Wu, G.; Robertson, D. H.; Brooks, C. L., 3rd; Vieth, M., Detailed analysis of
grid-based molecular docking: A case study of CDOCKER-A CHARMm-based MD
docking algorithm. J Comput Chem 2003, 24, 1549-1562.
54.
Davis, I. W.; Baker, D., RosettaLigand docking with full ligand and receptor
flexibility. Journal of Molecular Biology 2009, 385, 381-392.
55.
Dunbrack, R. L., Jr.; Karplus, M., Backbone-dependent rotamer library for
proteins. Application to side-chain prediction. Journal of Molecular Biology 1993, 230,
543-574.
56.
Kolossavary, I.; Guida, W. C., Low-mode conformational search elucidated:
Application to C39H80 and flexible docking of 9-deazaguanine inhibitors into PNP.
Journal of Computational Chemistry 1999, 20, 1671-1684.
57.
Kolossvary, I.; Keseru, G. M., Hessian-free low-mode conformational search for
large-scale protein loop optimization: application to c-jun N-terminal kinase JNK3. J.
Comput. Chem. 2000, 22, 21-30.
58.
Lexa, K. W.; Carlson, H. A., Protein flexibility in docking and surface mapping.
Q. Rev. Biophys. 2012, 45, 301-343.
59.
Henzler, A. M.; Rarey, M., In Pursuit of Fully Flexible Protein-Ligand Docking:
Modeling the Bilateral Mechanism of Binding. Mol. Inf. 2010, 29, 164-173.
60.
Sotriffer, C. A., Accounting for induced-fit effects in docking: what is possible
and what is not? Curr Top Med Chem 2011, 11, 179-191.
61.
Agostino, M.; Jene, C.; Boyle, T.; Ramsland, P. A.; Yuriev, E., Molecular
Docking of Carbohydrate Ligands to Antibodies: Structural Validation against Crystal
Structures. J. Chem. Inf. Model. 2009, 49, 2749-2760.

96

62.
Jorgensen, W. L.; Maxwell, D. S.; Tirado-Rives, J., Development and Testing of
the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic
Liquids. J. Am. Chem. Soc. 1996, 118, 11225-11236.
63.
Vanommeslaeghe, K.; Hatcher, E.; Acharya, C.; Kundu, S.; Zhong, S.; Shim, J.;
Darian, E.; Guvench, O.; Lopes, P.; Vorobyov, I.; Mackerell, A. D., Jr., CHARMM
general force field: A force field for drug-like molecules compatible with the CHARMM
all-atom additive biological force fields. J Comput Chem 2010, 31, 671-690.
64.
Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A.,
Development and testing of a general Amber force field. J. Comput. Chem. 2004, 25,
1157-1174.
65.
Gadakar, P. K.; Phukan, S.; Dattatreya, P.; Balaji, V. N., Pose Prediction
Accuracy in Docking Studies and Enrichment of Actives in the Active Site of GSK-3β. J.
Chem. Inf. Model. 2007, 47, 1446-1459.
66.
Celik, L.; Sinning, S.; Severinsen, K.; Hansen, C. G.; Moller, M. S.; Bols, M.;
Wiborg, O.; Schiott, B., Binding of Serotonin to the Human Serotonin Transporter.
Molecular Modeling and Experimental Validation. J. Am. Chem. Soc. 2008, 130, 38533865.
67.
Liao, C.; Park, J.-E.; Bang, J. K.; Nicklaus, M. C.; Lee, K. S., Probing Binding
Modes of Small Molecule Inhibitors to the Polo-Box Domain of Human Polo-like Kinase
1. ACS Med. Chem. Lett. 2010, 1, 110-114.
68.
Felts, A. K.; LaBarge, K.; Bauman, J. D.; Patel, D. V.; Himmel, D. M.; Arnold,
E.; Parniak, M. A.; Levy, R. M., Identification of Alternative Binding Sites for Inhibitors
of HIV-1 Ribonuclease H Through Comparative Analysis of Virtual Enrichment Studies.
J. Chem. Inf. Model. 2011, 51, 1986-1998.
69.
Babaoglu, K.; Shoichet, B. K., Deconstructing fragment-based inhibitor
discovery. Nat. Chem. Biol. 2006, 2, 720-723.
70.
McRobb, F. M.; Capuano, B.; Crosby, I. T.; Chalmers, D. K.; Yuriev, E.,
Homology Modeling and Docking Evaluation of Aminergic G Protein-Coupled
Receptors. J. Chem. Inf. Model. 2010, 50, 626-637.
71.
Barreca, M. L.; Iraci, N.; De Luca, L.; Chimirri, A., Induced-Fit Docking
Approach Provides Insight into the Binding Mode and Mechanism of Action of HIV-1
Integrase Inhibitors. ChemMedChem 2009, 4, 1446-1456.
72.
Sutton, M.; Atweh, G. F.; Cashman, T. D.; Davis, W. T., Resolving conflicts:
misconceptions and myths in the care of the patient with sickle cell disease. Mt Sinai J
Med 1999, 66, 282-285.

97

73.
Kotiah, S. D.; Ballas, S. K., Investigational drugs in sickle cell anemia. Expert
Opin. Invest. Drugs 2009, 18, 1817-1828.
74.
Frenette, P. S.; Atweh, G. F., Sickle cell disease: old discoveries, new concepts,
and future promise. J. Clin. Invest. 2007, 117, 850-858.
75.
Colombatti, R.; Maschietto, N.; Varotto, E.; Grison, A.; Grazzina, N.;
Meneghello, L.; Teso, S.; Carli, M.; Milanesi, O.; Sainati, L., Pulmonary hypertension in
sickle cell disease children under 10 years of age. Br. J. Haematol. 2010, 150, 601-609.
76.
de Franceschi, L.; Finco, G.; Vassanelli, A.; Zaia, B.; Ischia, S.; Corrocher, R., A
pilot study on the efficacy of ketorolac plus tramadol infusion combined with
erythrocytapheresis in the management of acute severe vaso-occlusive crises and sickle
cell pain. Haematologica 2004, 89, 1389-1391.
77.
Tang, D. C.; Prauner, R.; Liu, W.; Kim, K.-H.; Hirsch, R. P.; Driscoll, M. C.;
Rodgers, G. P., Polymorphisms within the angiotensinogen gene (GT-repeat) and the risk
of stroke in pediatric patients with sickle cell disease: A case-control study. Am. J.
Hematol. 2001, 68, 164-169.
78.
Olowoyeye, A.; Okwundu Charles, I., Gene therapy for sickle cell disease.
Cochrane Database Syst Rev 2010, CD007652.
79.
Steinberg, M. H.; Brugnara, C., Pathophysiological-based approaches to treatment
of sickle cell disease. Annu. Rev. Med. 2003, 54, 89-112.
80.
Lou, T.-F.; Singh, M.; Mackie, A.; Li, W.; Pace Betty, S., Hydroxyurea generates
nitric oxide in human erythroid cells: mechanisms for gamma-globin gene activation. Exp
Biol Med (Maywood) 2009, 234, 1374-1382.
81.
Watson, J.; Stahman, A. W.; Bilello, F. P., The significance of the paucity of
sickle cells in newborn negro infants. Am. J. Med. Sci. 1948, 215, 419-423.
82.
Michael Hall, A. N., Susan Smith, A foundation for neonatal care: a multidisciplinary guide. 1 ed.; Radcliffe Medical PR: 2009; p 258.
83.
Charache, S.; Terrin, M. L.; Moore, R. D.; Dover, G. J.; Barton, F. B.; Eckert, S.
V.; McMahon, R. P.; Bonds, D. R., Effect of hydroxyurea on the frequency of painful
crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in
Sickle Cell Anemia. N Engl J Med 1995, 332, 1317-1322.
84.
Weiner, D. L.; Hibberd, P. L.; Betit, P.; Copper, A. B.; Botelho, C. A.; Brugunara,
C., Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in
pediatric patients with sickle cell disease. JAMA, J. Am. Med. Assoc. 2003, 289, 11361142.

98

85.
Cokic, V. P.; Smith, R. D.; Beleslin-Cokic, B. B.; Njoroge, J. M.; Miller, J. L.;
Gladwin, M. T.; Schechter, A. N., Hydroxyurea induces fetal hemoglobin by the nitric
oxide-dependent activation of soluble guanylyl cyclase. J. Clin. Invest. 2003, 111, 231239.
86.
Singh, H.; Dulhani, N.; Kumar, B. N.; Singh, P.; Tiwari, P., Effective control of
sickle cell disease with hydroxyurea therapy. Indian J. Pharmacol. 2010, 42, 32-35.
87.
King, S. B., The nitric oxide producing reactions of hydroxyurea. Curr. Med.
Chem. 2003, 10, 437-452.
88.
Huang, J.; Zou, Z.; Kim-Shapiro, D. B.; Ballas, S. K.; King, S. B., Hydroxyurea
Analogues As Kinetic and Mechanistic Probes of the Nitric Oxide Producing Reactions
of Hydroxyurea and Oxyhemoglobin. J. Med. Chem. 2003, 46, 3748-3753.
89.
Rohrman, B. A.; Mazziotti, D. A., Quantum Chemical Design of Hydroxyurea
Derivatives for the Treatment of Sickle-Cell Anemia. J. Phys. Chem. B 2005, 109,
13392-13396.
90.
King, S. B., N-hydroxyurea and acyl nitroso compounds as nitroxyl (HNO) and
nitric oxide (NO) donors. Curr. Top. Med. Chem. (Sharjah, United Arab Emirates) 2005,
5, 665-673.
91.
Lepeshkevich, S. V.; Parkhats, M. V.; Stepuro, I. I.; Dzhagarov, B. M., Molecular
oxygen binding with α and β subunits within the R quaternary state of human hemoglobin
in solutions and porous sol-gel matrices. Biochim. Biophys. Acta, Proteins Proteomics
2009, 1794, 1823-1830.
92.
Safo, M. K.; Ahmed, M. H.; Ghatge, M. S.; Boyiri, T., Hemoglobin-ligand
binding: Understanding Hb function and allostery on atomic level. Biochim. Biophys.
Acta, Proteins Proteomics 2011, 1814, 797-809.
93.
Park, S.-Y.; Yokoyama, T.; Shibayama, N.; Shiro, Y.; Tame, J. R. H., 1.25 Å
resolution crystal structures of human hemoglobin in the oxy, deoxy and carbonmonoxy
forms. J. Mol. Biol. 2006, 360, 690-701.
94.
Yuan, Y.; Simplaceanu, V.; Ho, N. T.; Ho, C., An Investigation of the Distal
Histidyl Hydrogen Bonds in Oxyhemoglobin: Effects of Temperature, pH, and Inositol
Hexaphosphate. Biochemistry 2010, 49, 10606-10615.
95.
Kanias, T.; Acker, J. P., Biopreservation of red blood cells - the struggle with
hemoglobin oxidation. Febs J. 2010, 277, 343-356.
96.
Bellelli, A., Hemoglobin and cooperativity: experiments and theories. Curr.
Protein Pept. Sci. 2010, 11, 2-36.

99

97.
Yonetani, T.; Laberge, M., Protein dynamics explain the allosteric behaviors of
hemoglobin. Biochim. Biophys. Acta, Proteins Proteomics 2008, 1784, 1146-1158.
98.
Dzhagarov, B. M.; Lepeshkevich, S. V., Kinetic studies of differences between αand β-chains of human hemoglobin: an approach for determination of the chain affinity to
oxygen. Chem. Phys. Lett. 2004, 390, 59-64.
99.
Umbreit, J., Methemoglobin-it's not just blue: a concise review. Am. J. Hematol.
2007, 82, 134-144.
100. King, S. B., C-Nitroso compounds, oximes, N-hydroxyguanidines and Nhydroxyureas. Nitric Oxide Donors 2005, 177-199.
101. Huang, J.; Hadimani, S. B.; Rupon, J. W.; Ballas, S. K.; Kim-Shapiro, D. B.;
King, S. B., Iron Nitrosyl Hemoglobin Formation from the Reactions of Hemoglobin and
Hydroxyurea. Biochemistry 2002, 41, 2466-2474.
102. Pacelli, R.; Taira, J.; Cook, J. A.; Wink, D. A.; Krishna, M. C., Hydroxyurea
reacts with heme proteins to generate nitric oxide. Lancet 1996, 347, 900.
103. Konc, J.; Cesnik, T.; Konc, J. T.; Penca, M.; Janezic, D., ProBiS-Database:
Precalculated Binding Site Similarities and Local Pairwise Alignments of PDB
Structures. J. Chem. Inf. Model. 2012, 52, 604-612.
104. Konc, J.; Janezic, D., ProBiS algorithm for detection of structurally similar
protein binding sites by local structural alignment. Bioinformatics 2010, 26, 1160-1168.
105. Konc, J.; Janezic, D., ProBiS: a web server for detection of structurally similar
protein binding sites. Nucleic Acids Res. 2010, 38, W436-W440.
106. Larkin, M. A.; Blackshields, G.; Brown, N. P.; Chenna, R.; McGettigan, P. A.;
McWilliam, H.; Valentin, F.; Wallace, I. M.; Wilm, A.; Lopez, R.; Thompson, J. D.;
Gibson, T. J.; Higgins, D. G., Clustal W and Clustal X version 2.0. Bioinformatics 2007,
23, 2947-2948.
107. Chen, H.; Ikeda-Saito, M.; Shaik, S., Nature of the Fe-O2 Bonding in OxyMyoglobin: Effect of the Protein. J. Am. Chem. Soc. 2008, 130, 14778-14790.
108. Park, S.-Y.; Yokoyama, T.; Shibayama, N.; Shiro, Y.; Tame Jeremy, R. H., 1.25
A resolution crystal structures of human haemoglobin in the oxy, deoxy and
carbonmonoxy forms. J Mol Biol 2006, 360, 690-701.
109. Dodson, E.; Dodson, G., Movements at the hemoglobin A-hemes and their role in
ligand binding, analyzed by X-ray crystallography. Biopolymers 2009, 91, 1056-1063.

100

110. De Rosa, M. C.; Alinovi, C. C.; Russo, A.; Giardina, B., Binding modes of L35 to
α- and β-semihemoglobins: Structural insights into the inequivalence of α- and β-subunits
of hemoglobin. Biochem. Biophys. Res. Commun. 2007, 354, 720-726.
111. Marechal, J.-D.; Maseras, F.; Lledos, A.; Mouawad, L.; Perahia, D., A DFT study
on the relative affinity for oxygen of the α and β subunits of hemoglobin. J. Comput.
Chem. 2006, 27, 1446-1453.
112. Birukou, I.; Schweers, R. L.; Olson, J. S., Distal Histidine Stabilizes Bound O2
and Acts as a Gate for Ligand Entry in Both Subunits of Adult Human Hemoglobin. J.
Biol. Chem. 2010, 285, 8840-8854.
113. Lukin, J. A.; Simplaceanu, V.; Zou, M.; Ho, N. T.; Ho, C., NMR reveals
hydrogen bonds between oxygen and distal histidines in oxyhemoglobin. Proc. Natl.
Acad. Sci. U. S. A. 2000, 97, 10354-10358.
114. Suzuki, T.; Watanabe, Y.-H.; Nagasawa, M.; Matsuoka, A.; Shikama, K., Dual
nature of the distal histidine residue in the autoxidation reaction of myoglobin and
hemoglobin. Comparison of the H64 mutants. Eur. J. Biochem. 2000, 267, 6166-6174.
115. Jacobson, M. P.; Pincus, D. L.; Rapp, C. S.; Day, T. J. F.; Honig, B.; Shaw, D. E.;
Friesner, R. A., A hierarchical approach to all-atom protein loop prediction. Proteins
Struct., Funct., Bioinf. 2004, 55, 351-367.
116. Brooks, B. R.; Brooks, I. I. I. C. L.; Mackerell, J. A. D.; Nilsson, L.; Petrella, R.
J.; Roux, B.; Won, Y.; Archontis, G.; Bartels, C.; Boresch, S.; Caflisch, A.; Caves, L.;
Cui, Q.; Dinner, A. R.; Feig, M.; Fischer, S.; Gao, J.; Hodoscek, M.; Im, W.; Kuczera,
K.; Lazaridis, T.; Ma, J.; Ovchinnikov, V.; Paci, E.; Pastor, R. W.; Post, C. B.; Pu, J. Z.;
Schaefer, M.; Tidor, B.; Venable, R. M.; Woodcock, H. L.; Wu, X.; Yang, W.; York, D.
M.; Karplus, M., CHARMM: The Biomolecular Simulation Program. J. Comp. Chem.
2009, 30, 1545-1614.
117. Miller, B. T.; Singh, R. P.; Klauda, J. B.; Hodoscek, M.; Brooks, B. R.;
Woodcock, H. L., III, CHARMMing: A New, Flexible Web Portal for CHARMM. J.
Chem. Inf. Model. 2008, 48, 1920-1929.
118. Misra, H. P.; Fridovich, I., Generation of superoxide radical during the
autoxidation of hemoglobin. J. Biol. Chem. 1972, 247, 6960-6962.
119. Konc, J. J., D., An Improved Branch and Bound Algorithm for the Maximum
Clique Problem MATCH Commun. Math. Comput. Chem. 2007, 58, 569– 590.
120. Simonneaux, G.; Bondon, A., Mechanism of electron transfer in heme proteins
and models: The NMR approach. Chem. Rev. (Washington, DC, U. S.) 2005, 105, 26272646.

101

121. Kiger, L.; Marden, M. C., Electron transfer kinetics between hemoglobin
subunits. J. Biol. Chem. 2001, 276, 47937-47943.
122. Li, C.-z.; Liu, G.; Prabhulkar, S., Comparison of kinetics of hemoglobin electron
transfer in solution and immobilized on electrode surface. Am. J. Biomed. Sci. 2009, 1,
283-294.
123. Huang, J.; Kim-Shapiro, D. B.; King, S. B., Catalase-Mediated Nitric Oxide
Formation from Hydroxyurea. J. Med. Chem. 2004, 47, 3495-3501.
124. Juul, T.; Malolepszy, A.; Dybkaer, K.; Kidmose, R.; Rasmussen, J. T.; Andersen,
G. R.; Johnsen, H. E.; Jorgensen, J.-E.; Andersen, S. U., The in Vivo Toxicity of
Hydroxyurea Depends on Its Direct Target Catalase. J. Biol. Chem. 2010, 285, 2141121415.
125. Chiang, E. Y.; Frenette, P. S., Sickle cell vaso-occlusion. Hematol Oncol Clin
North Am. 2005, 19, 771-784.
126. Stuart, M. J.; Setty, B. N. Y., Sickle cell acute chest syndrome: pathogenesis and
rationale for treatment. Blood 1999, 94, 1555-1560.
127. Lanzkron, S.; Haywood, C., Jr.; Hassell, K. L.; Rand, C., Provider barriers to
hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease
Adult Provider Network. Journal of the National Medical Association 2008, 100, 968973.
128. Strouse, J. J.; Lanzkron, S.; Beach, M. C.; Haywood, C.; Park, H.; Witkop, C.;
Wilson, R. F.; Bass, E. B.; Segal, J. B., Hydroxyurea for sickle cell disease: a systematic
review for efficacy and toxicity in children. Pediatrics 2008, 122, 1332-1342.
129. Silva, D. G. H.; Belini, E., Jr.; Torres, L. d. S.; Ricci, O., Jr.; Lobo, C. d. C.;
Bonini-Domingos, C. R.; Alves, d. A. E., Relationship between oxidative stress,
glutathione S-transferase polymorphisms and hydroxyurea treatment in sickle cell
anemia. Blood Cells, Molecules, & Diseases 2011, 47, 23-28.
130. King, S. B., Mechanisms and novel directions in the biological applications of
nitric oxide donors. Free Radical Biology & Medicine 2004, 37, 735-736.
131. Rupon, J. W.; Domingo, S. R.; Smith, S. V.; Gummadi, B. K.; Shields, H.; Ballas,
S. K.; King, S. B.; Kim-Shapiro, D. B., The reactions of myoglobin, normal adult
hemoglobin, sickle cell hemoglobin and hemin with hydroxyurea. Biophysical Chemistry
2000, 84, 1-11.
132. Goyal, M. M.; Basak, A., Human catalase: looking for complete identity. Protein
& Cell 2010, 1, 888-897.

102

133. Fernandez-Lafuente, R., Stabilization of multimeric enzymes: Strategies to
prevent subunit dissociation. Enzyme and Microbial Technology 2009, 45, 405-418.
134. Wood, K. C.; Granger, D. N., Sickle cell disease: role of reactive oxygen and
nitrogen metabolites. Clinical and Experimental Pharmacology and Physiology 2007, 34,
926-932.
135. Rovira, C.; Alfonso-Prieto, M.; Biarnes, X.; Carpena, X.; Fita, I.; Loewen, P. C.,
A first principles study of the binding of formic acid in catalase complementing high
resolution X-ray structures. Chemical Physics 2006, 323, 129-137.
136.
37.

Fita, I.; Rossmann, M. G., The active center of catalase. J Mol Biol 1985, 185, 21-

137. Alfonso-Prieto, M.; Biarnes, X.; Vidossich, P.; Rovira, C., The Molecular
Mechanism of the Catalase Reaction. J. Am. Chem. Soc. 2009, 131, 11751-11761.
138. Putnam, C. D.; Arvai, A. S.; Bourne, Y.; Tainer, J. A., Active and inhibited
human catalase structures: Ligand and NADPH binding and catalytic mechanism. J Mol
Biol 2000, 296, 295-309.
139. Banks, J. L.; Beard, H. S.; Cao, Y.; Cho, A. E.; Damm, W.; Farid, R.; Felts, A.
K.; Halgren, T. A.; Mainz, D. T.; Maple, J. R.; Murphy, R.; Philipp, D. M.; Repasky, M.
P.; Zhang, L. Y.; Berne, B. J.; Friesner, R. A.; Gallicchio, E.; Levy, R. M., Integrated
modeling program, applied chemical theory (IMPACT). Journal of Computational
Chemistry 2005, 26, 1752-1780.
140.

Schr??dinger, L. L. C., LigPrep, version 2.3. 2009.

141. Coutsias, E. A.; Seok, C.; Jacobson, M. P.; Dill, K. A., A kinematic view of loop
closure. J. Comput. Chem. 2004, 25, 510-528.
142. Gadakar, P. K.; Phukan, S.; Dattatreya, P.; Balaji, V. N., Pose Prediction
Accuracy in Docking Studies and Enrichment of Actives in the Active Site of GSK-3Î? J
Chem Inf Model 2007, 47, 1446-1459.
143. Xiang, Z.; Honig, B., Extending the accuracy limits of prediction for side-chain
conformations. J Mol Biol 2001, 311, 421-430.
144. Brooks, B. R.; Brooks, C. L., III; Mackerell, A. D., Jr.; Nilsson, L.; Petrella, R. J.;
Roux, B.; Won, Y.; Archontis, G.; Bartels, C.; Boresch, S.; Caflisch, A.; Caves, L.; Cui,
Q.; Dinner, A. R.; Feig, M.; Fischer, S.; Gao, J.; Hodoscek, M.; Im, W.; Kuczera, K.;
Lazaridis, T.; Ma, J.; Ovchinnikov, V.; Paci, E.; Pastor, R. W.; Post, C. B.; Pu, J. Z.;
Schaefer, M.; Tidor, B.; Venable, R. M.; Woodcock, H. L.; Wu, X.; Yang, W.; York, D.
M.; Karplus, M., CHARMM: The biomolecular simulation program. J. Comput. Chem.
2009, 30, 1545-1614.
103

145. Woodcock, H. L., III; Hodoscek, M.; Gilbert, A. T. B.; Gill, P. M. W.; Schaefer,
H. F., III; Brooks, B. R., Interfacing Q-chem and CHARMM to perform QM/MM
reaction path calculations. Journal of Computational Chemistry 2007, 28, 1485-1502.
146. Vankayala, S. L.; Hargis, J. C.; Woodcock, H. L., Unlocking the Binding and
Reaction Mechanism of Hydroxyurea Substrates as Biological Nitric Oxide Donors. J
Chem Inf Model 2012, 52, 1288-1297.
147. McGann, P. T.; Ware, R. E., Hydroxyurea for sickle cell anemia: what have
learned and what questions still remain? Current Opinion in Hematology 2011, 18, 158165.
148. Karimi, M.; Zekavat, O. R.; Sharifzadeh, S.; Mosavizadeh, K., Clinical response
of patients with sickle cell anemia to cromolyn sodium nasal spray. Am. J. Hematol.
2006, 81, 809-816.
149. Vrcek, I. V.; Sakic, D.; Vrcek, V.; Zipse, H.; Birus, M., Computational study of
radicals derived from hydroxyurea and its methylated analogues. Organic &
Biomolecular Chemistry 2012, 10, 1196-1206.
150. Donzelli, S.; Espey, M. G.; Flores-Santana, W.; Switzer, C. H.; Yeh, G. C.;
Huang, J.; Stuehr, D. J.; King, S. B.; Miranda, K. M.; Wink, D. A., Generation of nitroxyl
by heme protein-mediated peroxidation of hydroxylamine but not N-hydroxy-L-arginine.
Free Radical Biology & Medicine 2008, 45, 578-584.
151. Alfonso-Prieto, M.; Vidossich, P.; Rovira, C., The reaction mechanisms of heme
catalases: An atomistic view by ab initio molecular dynamics. Archives of Biochemistry
and Biophysics 2012, 525, 121-130.
152. Zipse, H., Radical stability - a theoretical perspective. Topics in Current
Chemistry 2006, 263, 163-189.
153. Pegg, A. E., Repair of O6-alkylguanine by alkyltransferases. Mutation Res. 2000,
462, 83-100.
154. Margison, G.; Povey, A. C.; Kaina, B.; Santibáñez-Koref, M. F., Variability and
regulation of O6-alkylguanine-DNA alkyltransferase. Carcinogenesis 2003, 24, 625-635.
155. Tubbs, J. L.; Pegg, A. E.; Tainer, J. A., DNA binding, nucleotide flipping, and the
helix-turn-helix motif in base repair by O6-alkylguanine-DNA alkyltransferase and its
implications for cancer chemotherapy. DNA Repair (Amst) 2007, 6, 1100-1115.
156. Gerson, S. L., MGMT: its role in cancer aetiology and cancer therapeutics. Nat.
Rev. Cancer 2004, 4, 296-307.

104

157. Pegg, A. E.; Dolan, M. E., Overcoming resistance to alkylating agents by
inhibitors of O6-alkylguanine-DNA alkyltransferase. In DNA Repair in Cancer Therapy,
Panasci, L. C.; Alaoui-Jamali, M., Eds. Humana Press, NJ: 2004; pp 143-177.
158. Dolan, M. E.; Pegg, A. E., O6-Benzylguanine and its role in chemotherapy.
Clinical Cancer Res. 1997, 3, 837-847.
159. Middleton, M. R.; Margison, G. P., Improvement of chemotherapy efficacy by
inactivation of a DNA-repair pathway. Lancet Oncol. 2003, 4, 37-44.
160. Khan, O.; Middleton, M. R., The therapeutic potential of O6-alkylguanine DNA
alkyltransferase inhibitors. Expert Opin. Investig. Drugs 2007, 16, 1573-1584.
161. Dolan, M. E.; Moschel, R. C.; Pegg, A. E., Depletion of mammalian O6alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to
evaluate the role of this protein in protection against carcinogenic and therapeutic
alkylating agents. Proc. Natl. Acad. Sci. U. S. A. 1990, 87, 5368-5372.
162. Pegg, A. E.; Boosalis, M.; Samson, L.; Moschel, R. C.; Byers, T. L.; Swenn, K.;
Dolan, M. E., Mechanism of inactivation of human O6-alkylguanine-DNA
alkyltransferase by O6-benzylguanine. Biochemistry 1993, 32, 11998-12006.
163. Daniels, D. S.; Mol, C. D.; Arvai, A. S.; Kanugula, S.; Pegg, A. E.; Tainer, J. A.,
Active and alkylated human AGT structures: a novel zinc site, inhibitor and extrahelical
binding. DNA damage reversal revealed by mutants and structures of active and alkylated
human AGT. Embo J. 2000, 19, 1719-1730.
164. McElhinney, R. S.; Donnelly, D. J.; McCormick, J. E.; Kelly, J.; Watson, A. J.;
Rafferty, J. A.; Elder, R. H.; Middleton, M. R.; Willington, M. A.; McMurry, T. B. H.;
Margison, G. P., Inactivation of O6-alkylguanine-DNA alkyltransferase 1. Novel O6(hetarylmethyl)guanines having basic rings in the side chain. J. Med. Chem. 1998, 41,
5265-5271.
165. Quinn, J. A.; Desjardins, A.; Weingart, J.; Brem, H.; Dolan, M. E.; Delaney, S.
M.; Vredenburgh, J.; Rich, J.; Friedman, A. H.; Reardon, D. A.; Sampson, J. H.; Pegg, A.
E.; Moschel, R. C.; Birch, R.; McLendon, R. E.; Provenzale, J. M.; Gururangan, S.;
Dancey, J. E.; Maxwell, J.; Tourt-Uhlig, S.; Herndon, J. E., 2nd; Bigner, D. D.;
Friedman, H. S., Phase I trial of temozolomide plus O6-benzylguanine for patients with
recurrent or progressive malignant glioma. J. Clin. Oncol. 2005, 23, 7178-7187.
166. Warren, K. E.; Aikin, A. A.; Libucha, M.; Widemann, B. C.; Fox, E.; Packer, R.
J.; Balis, F. M., Phase I study of O6-benzylguanine and temozolomide administered daily
for 5 days to pediatric patients with solid tumors. J. Clin. Oncol. 2005, 23, 7646-7653.

105

167. Broniscer, A.; Gururangan, S.; MacDonald, T. J.; Goldman, S.; Packer, R. J.;
Stewart, C. F.; Wallace, D.; Danks, M. K.; Friedman, H. S.; Poussaint, T. Y.; Kun, L. E.;
Boyett, J. M.; Gajjar, A., Phase I trial of single-dose temozolomide and continuous
administration of O6-benzylguanine in children with brain tumors: a pediatric brain tumor
consortium report. Clin. Cancer Res. 2007, 13, 6712-6718.
168. Batts, E. D.; Maisel, C.; Kane, D.; Liu, L.; Fu, P.; O'Brien, T.; Remick, S.; Bahlis,
N.; Gerson, S. L., O6-Benzylguanine and BCNU in multiple myeloma: a phase II trial.
Cancer Chemother. Pharmacol. 2007, 60, 415-421.
169. Gajewski, T. F.; Sosman, J.; Gerson, S. L.; Liu, L.; Dolan, E.; Lin, S.; Vokes, E.
E., Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine
and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. Clin. Cancer Res. 2005,
11, 7861-7865.
170. Ranson, M.; Middleton, M. R.; Bridgewater, J.; Lee, S. M.; Dawson, M.; Jowle,
D.; Halbert, G.; Waller, S.; McGrath, H.; Gumbrell, L.; McElhinney, R. S.; Donnelly, D.;
McMurry, T. B.; Margison, G. P., Lomeguatrib, a potent inhibitor of O6-alkylguanineDNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and
evaluation in combination with temozolomide in patients with advanced solid tumors.
Clin. Cancer Res. 2006, 12, 1577-1584.
171. Daniels, D. S.; Woo, T. T.; Luu, K. X.; Noll, D. M.; Clarke, N. D.; Pegg, A. E.;
Tainer, J. A., Novel modes of DNA binding and nucleotide flipping by the human DNA
repair protein AGT. Nat. Struct. Mol. Biol. 2004, 11, 714-720.
172. Guengerich, F. P.; Fang, Q.; Liu, L.; Hachey, D. L.; Pegg, A. E., O6Alkylguanine-DNA alkyltransferase: Low pKa and reactivity of cysteine 145.
Biochemistry 2003, 42, 10965-10970.
173. Xu-Welliver, M.; Pegg, A. E., Point mutations at multiple sites including highly
conserved amino acids maintain activity but render O6-alkylguanine-DNA
alkyltransferase insensitive to O6-benzylguanine. Biochem J 2000, 347, 519-526.
174. Pegg, A. E.; Xu-Welliver, M.; Loktionova, N. A., The DNA repair protein O6alkylguanine-DNA alkyltransferase as a target for cancer chemotherapy. In DNA
alterations in cancer: genetic and epigenetic changes, M. Ehrlich, E., Ed. Eaton
Publishing: Natick, MA, 2000; pp 471-488.
175. Pegg, A. E.; Goodtzova, K.; Loktionova, N. A.; Kanugula, S.; Pauly, G. T.;
Moschel, R. C., Inactivation of human O6-alkylguanine-DNA alkyltransferase by
modified oligodeoxyribonucleotides containing O6-benzylguanine. J. Pharm. Exp. Ther.
2001, 296, 958-965.

106

176. Luu, K. X.; Kanugula, S.; Pegg, A. E.; Pauly, G. T.; Moschel, R. C., Repair of
oligodeoxyribonucleotides by O6-alkylguanine-DNA alkyltransferase. Biochemistry
2002, 41, 8689-8697.
177. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz,
D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.;
Shenkin, P. S., Glide: a new approach for rapid, accurate docking and scoring. 1. Method
and assessment of docking accuracy. J. Med. Chem. 2004, 47, 1739-1749.
178. Halgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Pollard,
W. T.; Banks, J. L., Glide: a new approach for rapid, accurate docking and scoring. 2.
Enrichment factors in database screening. J. Med. Chem. 2004, 47, 1750-1759.
179. Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.;
Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T., Extra precision glide: docking and
scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J.
Med. Chem. 2006, 49, 6177-6196.
180. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.;
IShindyalov, I. N.; Bourne, P. E., The Protein Data Ban. Nucleic Acids Res. 2000, 28,
235-242.
181. Cho, A. E.; Guallar, V.; Berne, B.; Friesner, R. A., Importance of accurate
charges in molecular mocking: quantum mechanical/molecular mechanical (QM/MM)
approach. J. Comput. Chem. 2005, 26, 915-931.
182. Bytheway, I.; Cochran, S., Validation of molecular docking calculations involving
FGF-1 and FGF-2. J. Med. Chem. 2004, 47, 1683-1693.
183. Goodtzova, K.; Crone, T.; Pegg, A. E., Activation of human O6-alkylguanineDNA alkyltransferase by DNA. Biochemistry 1994, 33, 8385-8390.
184. Pegg, A. E.; Chung, L.; Moschel, R. C., Effect of DNA on the inactivation of O6alkylguanine-DNA alkyltransferase by 9-substituted O6-benzylguanine derivatives.
Biochem. Pharmacol. 1997, 53, 1559-1564.
185. Nelson, M. E.; Loktionova, N. A.; Pegg, A. E.; Moschel, R. C., 2-Amino-O4benzylpteridine
derivatives:
potent
inactivators
of
O6-alkylguanine-DNA
alkyltransferase. J. Med. Chem. 2004, 47, 3887-3891.

107

Appendices

Appendix A. Supporting information and copyright permissions for chapter 2

Figure A-1: Generic representation of second lowest energy
hydroxyurea analog IFD structures, 8 is shown as an example.

pose

for

all

A.1 Analysis of second low energy pose
The significant hydrogen bonding contribution of HN'

leads us to examine the best

binding pose of hydroxyurea analogs in OxyHb that involve hydrogen bonding with
HN' to residues other than Gly25. This pose had hydrogen bonding to Od for all analogs
except 1 and 7. All IFD poses generated for 1 have hydrogen bonding to the OGly25. The
generic representation of this pose is depicted in Figure A1. We postulate that these
108

orientations will not be highly populated since the hydroxyurea analog radicals
formed in reaction scheme 1 (Figure 7) cannot be stabilized in MetHb as the oxygen
would be transformed into hydrogen peroxide and leaves the active site. The results also
reveal that these binding poses have low favorable binding energies compared to the
binding poses of HU analogs that has HN' hydrogen bonded to OGly25. These results
convinced us that the second pose is a less populated low energy binding pose or
may not even exist.

Figure A-2: Image retrieved from local structure similarity profile webpage for
Adult Hemoglobin (HbA) protein (PDB/Chain ID: 2DN1/A). The heme is represented in
stick model, conserved residues colored red in CPK, and the protein in cartoon
representation. The rainbow colored band shows the structural similar of residues
ranging from blue (variable) to red (structurally conserved).
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Figure A-3: Mutiple sequence alignment studies of human globin chains includes
α-Hb, δ-Hb, β-Hb, Cytoglobin, Myoglobin and Human Neuroglobin using ClustalW2
in which 2DN1-A is used as the query protein. Legends given below the sequences
represent residues that are identical ("*"), observed conserved substitutions (":"), and
observed semi-conserved substitutions ("."). The amino acid residues are colored
according to their physiochemical properties in which red implies small
hydrophobic (AFILMPVWY); blue implies acidic (DE); purple implies basic (HKR)
and green implies with hydroxyls and amines and basic too (CGHNQSTY)

A.2 Sequence alignment studies
Multiple sequence alignment

studies

were performed

using globin

sequences

suggested by ProBiS. ClustalW2 was used to align selected proteins with the query
sequence and visually inspect active site conserved residues (Figure A3).
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A.3 Permissions
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Appendix B. Supporting information for catalase work

Figure B-1: Predicted binding orientations of hydroxyurea analogs (3, and 4) pose
conformations in catalase CpdI.

Figure B-2: Modified analogs of 6 along with7
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Figure B-3: Predicted binding orientations of hydroxyurea analogs (6a, and 6b) that gave
pose A like conformations in catalase CpdI

Figure B-4: Hydroxylamine reaction with catalase to produce HNO
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Figure B-5: Torsional angle Vs Energy plot
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